{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:01:36Z","timestamp":1789952496085,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012751","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000}}],"reference-count":663,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012751.pub2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:41:21Z","timestamp":1782211281000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis"],"prefix":"10.1002","volume":"2026","author":[{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K","family":"Akobeng","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology; Sidra Medicine; Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Health Sciences; University of Leicester; Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon William","family":"Moran","sequence":"additional","affiliation":[{"name":"National Institute of Health Research Nottingham Biomedical Research Centre; University of Nottingham and Nottingham University Hospitals; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Cherayath","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masitara","family":"Masitara","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Sherafat","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ibrahim","family":"Khan","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareed","family":"Alqusous","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assem","family":"Elleithy","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Phlananthachai","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Central Lancashire; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"10.1002\/14651858.CD012751.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12703\/P7-44","article-title":"Pathogenesis of Crohn's disease","volume":"7","author":"Boyapati","year":"2015","journal-title":"F1000Prime Reports"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11894-019-0705-6","article-title":"Evolving epidemiology of IBD","volume":"21","author":"Windsor","year":"2019","journal-title":"Current Gastroenterology Reports"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","article-title":"Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis","volume":"163","author":"Nguyen","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11894-016-0522-0","article-title":"Next-generation therapeutics for inflammatory bowel disease","volume":"18","author":"Dulai","year":"2016","journal-title":"Current Gastroenterology Reports"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14728214.2024.2303116","article-title":"Novel and emerging drugs for the treatment of Crohn\u2019s disease: a review of phase II and III trials","volume":"29","author":"Wetwittayakhlang","year":"2024","journal-title":"Expert Opinion on Emerging Drugs"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"e0270749","DOI":"10.1371\/journal.pone.0270749","article-title":"Mechanisms of action of anti-inflammatory proteins and peptides with anti-TNF-alpha activity and their effects on the intestinal barrier: A systematic review","volume":"17","author":"Lima","year":"2022","journal-title":"PLOS One"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cgh.2006.04.022","article-title":"Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Rutgeerts","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/gutjnl-2012-302262","article-title":"Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol","volume":"62","author":"Hebuterne","year":"2013","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0014|cit14","first-page":"S592\u20133","article-title":"Vedolizumab exposure-response relationship during induction therapy in adults with Crohn\u2019s disease","volume":"146","author":"French","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD012751.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clinical Pharmacokinetics"},{"issue":"20","key":"10.1002\/14651858.CD012751.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.crohns.2014.04.007","article-title":"Clinical trials in luminal Crohn's disease: a historical perspective","volume":"8","author":"Hindryckx","year":"2014","journal-title":"Journal of Crohns and Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-024-02094-5","article-title":"Targeting the sphingosine-1-phosphate pathway: new opportunities in inflammatory bowel disease management","volume":"84","author":"Kitsou","year":"2024","journal-title":"Drugs"},{"issue":"11","key":"10.1002\/14651858.CD012751.pub2-BIB0020|cit20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012878.pub2","article-title":"Adalimumab for induction of remission in Crohn's disease","author":"Abbass","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD012751.pub2-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012623.pub2","article-title":"Infliximab for medical induction of remission in Crohn's disease","author":"Gordon","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0022|cit22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012609.pub2","article-title":"Infliximab for maintenance of medically-induced remission in Crohn's disease","author":"Gordon","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013611.pub2","article-title":"Vedolizumab for induction and maintenance of remission in Crohn's disease","author":"Hui","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013747.pub2","article-title":"Certolizumab pegol for maintenance of medically induced remission in Crohn\u2019s disease","author":"Okabayashi","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012877.pub2","article-title":"Adalimumab for maintenance of remission in Crohn's disease","author":"Townsend","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012893.pub2","article-title":"Certolizumab pegol for induction of remission in Crohn's disease","author":"Yamazaki","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"CD012751","DOI":"10.1002\/14651858.CD012751","article-title":"Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis","volume":"8","author":"Hindryckx","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/9781119536604.ch4","volume-title":"Cochrane Handbook for Systematic Reviews Interventions","author":"Lefebvre","year":"2019"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hir.12269","article-title":"Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study","volume":"36","author":"Glanville","year":"2019","journal-title":"Health Information and Libraries Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jclinepi.2021.02.002","article-title":"No limitations to language, date, publication type, and publication status in search step of systematic reviews","volume":"133","author":"Aali","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0033|cit33","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0034|cit34","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0036|cit36","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"7109","key":"10.1002\/14651858.CD012751.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the network graphs package","volume":"15","author":"Chaimani","year":"2015","journal-title":"Stata Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0041|cit41","unstructured":"R Development Core Team R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing 2009"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0042|cit42","unstructured":"Rucker G Schwarzer G Krahn U Package \u201cnetmeta\u201d: Network meta-analysis using frequentist methods (Version 0.7-0) http:\/\/cran.r-project.org\/web\/packages\/netmeta\/netmeta.pdf 2015"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0044|cit44","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"106","key":"10.1002\/14651858.CD012751.pub2-BIB0045|cit45","first-page":"1","article-title":"Netmeta: an r package for network meta-analysis using frequentist methods","volume":"23","author":"Balduzzi","year":"2023","journal-title":"Journal of Statistical Software"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0046|cit46","volume-title":"Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach (updated October 2013)","author":"Sch\u00fcnemann","year":"2013"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0047|cit47","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2022"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jclinepi.2018.04.013","article-title":"Corrigendum to \u201cAdvances in the GRADE approach to rate the certainty in estimates from a network meta-analysis\u201d [J Clin Epidemiol 2018; 93: 36-44]","volume":"98","author":"Brignardello-Petersen","year":"2018","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0050|cit50","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"108","key":"10.1002\/14651858.CD012751.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence","volume":"1","author":"Brignardello-Petersen","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1093\/ibd\/izaf085","article-title":"Developing IBD outcome effect size thresholds to inform research, guidelines, and clinical decisions","volume":"31","author":"Gordon","year":"2025","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0053|cit53","first-page":"jjad047","article-title":"A phase 2b, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study evaluating the safety and efficacy of tesnatilimab in patients with moderately to severely active Crohn\u2019s disease","volume":"no volume","author":"Allez","year":"2023","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0054|cit54","unstructured":"A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter protocol to evaluate the safety and efficacy of JNJ-64304500 in subjects with moderately to severely active Crohn\u2019s disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-000634-21-PL"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0055|cit55","unstructured":"Safety and efficacy study of JNJ-64304500 in participants with moderately to severely active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT02877134 2016"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0056|cit56","first-page":"jjad047","article-title":"A phase 2b, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study evaluating the safety and efficacy of tesnatilimab in patients with moderately to severely active Crohn\u2019s disease","volume":"no volume","author":"Allez","year":"2023","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284820938960","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial","volume":"13","author":"Chen","year":"2020","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0058|cit58","first-page":"A240","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease","volume":"6","author":"Chen","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0059|cit59","unstructured":"Study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT02499783"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012751.pub2-BIB0061|cit61","first-page":"S28","article-title":"Impact of adalimumab therapy after 12 weeks in patients with Crohn\u2019s disease who were nonresponders at week 4","volume":"14","author":"Panaccione","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0062|cit62","unstructured":"Adalimumab for the induction and maintenance of clinical remission in subjects with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00077779"},{"issue":"15","key":"10.1002\/14651858.CD012751.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1586\/egh.10.68","article-title":"Infliximab, azathioprine or combination therapy in the treatment of active Crohns disease","volume":"4","author":"Cottone","year":"2010","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1873-9946(13)60017-3","article-title":"Relationships between clinical remission, c-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the sonic trial","volume":"7","author":"Peyrin-Biroulet","year":"2013","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/S0016-5085(13)60808-2","article-title":"Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the sonic trial","volume":"144","author":"Peyrin-Biroulet","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, c-reactive protein normalisation and mucosal healing in Crohn's disease in the sonic trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0068|cit68","unstructured":"Multicenter, randomized, double-blind, active-controlled trial comparing REMICADE\u00ae (infliximab) and REMICADE\u00ae plus azathioprine to azathioprine in the treatment of patients with crohn\u2019s disease naive to both immunomodulators and biologic therapy (study of biologic and immunomodulator naive patients in crohn\u2019s disease) SONIC - SONIC https:\/\/trialsearch.who.int\/?TrialID=EUCTR2004-002815-10-GB"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a sonic post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0070|cit70","first-page":"A613","article-title":"Infliximab maintenance treatment results in lower hospitalization rate in Crohn's disease patients","volume":"122","author":"Colombel","year":"2002","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0071|cit71","first-page":"751f","article-title":"One year data from the sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"136","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0072|cit72","first-page":"S13","article-title":"Sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"15","author":"Sandborn","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0073|cit73","article-title":"Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"no volume","author":"Colombel","year":"2008","journal-title":"UEGW"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0075|cit75","first-page":"S31","article-title":"Endoscopic healing with cA2 anti-TNF antibodies in Crohn's disease: a European multicenter trial","volume":"28","author":"D'Haens","year":"1996","journal-title":"Endoscopy"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0076|cit76","article-title":"Anti-tumor necrosis factor-alpha (cA2) induces remission and endoscopic healing in active Crohn's disease: a double-blind, placebo-controlled study","volume":"60","author":"D'Haens","year":"1997","journal-title":"Acta Gastroenterologica Belgica"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"issue":"10340","key":"10.1002\/14651858.CD012751.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1053\/j.gastro.2021.06.037","article-title":"775a risankizumab induction therapy in patients with moderate-to-severe Crohn\u2019s disease with intolerance or inadequate response to conventional and\/or biologic therapy: results from the phase 3 ADVANCE study","volume":"161","author":"D'Haens","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0080|cit80","unstructured":"A study of the efficacy and safety of risankizumab in participants with moderately to severely active Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03105128"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1053\/j.gastro.2022.01.044","article-title":"Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results","volume":"162","author":"D\u2019Haens","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0082|cit82","unstructured":"A blinded study to evaluate higher versus standard adalimumab doses for induction and maintanance therapy in subjects with moderately to severely active crohn's disease and evidence of mucosal ulceration http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-001746-33-SK 2014"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0083|cit83","unstructured":"Study to evaluate efficacy and safety of two drug regimens in subjects with moderate to severe crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT02065570 2014"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0084|cit84","first-page":"229","article-title":"Efficacy of infliximab combined with azathioprine for moderate to severe Crohn's disease","volume":"18","author":"Duan","year":"2013","journal-title":"Chinese Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0086|cit86","unstructured":"Phase 2 study of the safety and efficacy of LDP-02 in mildly to moderately active Crohn's patients https:\/\/ClinicalTrials.gov\/show\/NCT00655135 2000"},{"issue":"20","key":"10.1002\/14651858.CD012751.pub2-BIB0087|cit87","first-page":"1946\u201360","article-title":"Ustekinumab induction therapy for Crohn's disease refractory to conventional or tumor necrosis factor antagonist therapy","volume":"375","author":"Feagan","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ecco-jcc\/jjw019.027","article-title":"Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's disease: results from the uniti-1 and uniti-2 studies","volume":"10","author":"Adedokun","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0089|cit89","first-page":"S","article-title":"Clinical characteristics, clinical response, and clinical remission status in adults treated with ustekinumab in the phase 3 UNITI studies at week 6 and week 44 by age at Crohn's disease onset","volume":"160","author":"Cohen","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0090|cit90","first-page":"A6","article-title":"A multicenter, double-blind, placebo (pbo)- controlled ph3 study of ustekinumab (ust), a human mab to IL-12\/23P40, in pts with moderately-severely active Crohn's disease (cd) who are naive or not refractory to antitnfa: UNITI-2","volume":"65","author":"Feagan","year":"2016","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1136\/gutjnl-2016-312388.5","article-title":"A multicenter, double-blind, placebo (pbo)-controlled ph3 study of ustekinumab (ust), a human IL-12\/23P40 mab, in moderate-severe Crohn's disease (CD) refractory to anti-TNFA: UNITI-1","volume":"65","author":"Rutgeerts","year":"2016","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0092|cit92","first-page":"A44","article-title":"Efficacy of ustekinumab for induction and maintenance of endoscopic healing in patients with Crohn's disease","volume":"4","author":"Rutgeerts","year":"2016","journal-title":"United European Gastroenterology Journal"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S595","DOI":"10.1016\/S0016-5085(17)32131-5","article-title":"Effect of maintenance ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease","volume":"152","author":"Feagan","year":"2017","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MIB.0000000000000720","article-title":"A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-1-\/-3p40 mab, in moderate-service Crohn's disease refractory to anti-TFNalpha: UNITI-1","volume":"22","author":"Sandborn","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0095|cit95","first-page":"1141","article-title":"Ustekinumab IV induction results in Crohn's disease symptom improvement within the first week in anti-TNF refractory patients","volume":"5","author":"Sandborn","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0096|cit96","first-page":"S403","article-title":"Ustekinumab IV induction results in Crohn's disease symptom improvement within the first week in anti-TNF refractory patients","volume":"112","author":"Sandborn","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0097|cit97","first-page":"S4","article-title":"Ustekinumab IV induction results in Crohn's disease symptom improvement within the first week in anti-TNF refractory patients","volume":"113","author":"Sandborn","year":"2018","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0098|cit98","first-page":"S390","article-title":"Assessment of serum c-reactive protein, faecal lactoferrin, and faecal calprotectin in patients with Crohn's disease: results from the uniti-1 and uniti-2 ustekinumab induction studies","volume":"10","author":"Gasink","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/ecco-jcc\/jjw019.013","article-title":"A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12\/23p40 mab, in moderate-severe Crohn's disease refractory to anti-tumour necrosis factor alpha: UNITI-1","volume":"10","author":"Rutgeerts","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ecco-jcc\/jjaa189","article-title":"Week 6 calprotectin best predicts likelihood of long-term endoscopic healing in Crohn's disease: a post-hoc analysis of the UNITI\/IM-UNITI trials","volume":"15","author":"Narula","year":"2021","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0101|cit101","unstructured":"Study to evaluate the safety and efficacy of ustekinumab in patients with moderately to severely active Crohn's disease who have failed or are intolerant to tumor necrosis factor (TNF) antagonist therapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-022758-18-BE 2011"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0102|cit102","first-page":"563","article-title":"A multicenter, double-blind, placebo-controlled ph3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn's disease who are not naive or not refractory to anti-TNFa: uniti-2","volume":"3","author":"Feagan","year":"2015","journal-title":"United European Gastroenterology Journal"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0103|cit103","first-page":"383","article-title":"A multicenter, double-blind, placebo-controlled ph3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn's disease who are naive or not refractory to anti-TNFA: Uniti-2","volume":"78","author":"Feagan","year":"2016","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"issue":"20","key":"10.1002\/14651858.CD012751.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0106|cit106","unstructured":"A study to evaluate the safety and efficacy of ustekinumab in patients with moderately to severely active Crohn's disease who have failed or are intolerant to tumor necrosis factor (TNF) antagonist therapy (UNITI-1) https:\/\/ClinicalTrials.gov\/show\/NCT01369329"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0107|cit107","first-page":"S73","article-title":"Reduced healthcare costs of Crohn's disease-related hospitalizations and surgeries in patients initiated with ustekinumab in the IM-UNITILTE study","volume":"24","author":"Obando","year":"2018","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1093\/ecco-jcc\/jjx180.799","article-title":"Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn's disease studies, by population","volume":"12","author":"Ghosh","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012751.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.14309\/00000434-201610001-00605","article-title":"Endoscopic healing in induction and maintenance with ustekinumab in the phase 3 UNITI Crohn's disease program","volume":"111","author":"Sandborn","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0110|cit110","unstructured":"A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab induction therapy in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to TNF antagonist therapy (UNITI-1) https:\/\/www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00005759"},{"issue":"20","key":"10.1002\/14651858.CD012751.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0112|cit112","first-page":"S","article-title":"Clinical characteristics, clinical response, and clinical remission status in adults treated with ustekinumab in the phase 3 UNITI studies at week 6 and week 44 by age at Crohn's disease onset","volume":"160","author":"Cohen","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ecco-jcc\/jjw019.027","article-title":"Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's disease: results from the UNITI-1 and UNITI-2 studies","volume":"10","author":"Adedokun","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0114|cit114","first-page":"S408","article-title":"Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn\u2019s disease with ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI studies","volume":"1","author":"Adedokun","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0115|cit115","first-page":"S26","article-title":"Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: results from the UNITI-1 and UNITI-2 phase 3 induction studies","volume":"10","author":"Li","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0116|cit116","first-page":"S","article-title":"Assessment of serum c-reactive protein, faecal lactoferrin, and faecal calprotectin in patients with Crohn's disease: results from the UNITI-1 and UNITI-2 ustekinumab induction studies","volume":"10","author":"Gasink","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0117|cit117","unstructured":"A study to evaluate the safety and efficacy of ustekinumab induction therapy in patients with moderately to severely active Crohn's disease http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-022759-42-NL 2011"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ecco-jcc\/jjaa189","article-title":"Week 6 calprotectin best predicts likelihood of long-term endoscopic healing in Crohn\u2019s disease: a post-hoc analysis of the UNITI\/IM-UNITI trials","volume":"15","author":"Narula","year":"2021","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0119|cit119","first-page":"563","article-title":"A multicenter, double-blind, placebo-controlled pH3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn's disease who are naive or not refractory to anti-TNFa: uniti-2","volume":"3","author":"Feagan","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/S0016-5085(13)60817-3","article-title":"Assessment of sleep impairment in patients with Crohn's disease: results from the ustekinumab CERTIFI study","volume":"1","author":"Gasink","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/ecco-jcc\/jjw019.013","article-title":"A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12\/23p40 mab, in moderate-severe Crohn's disease refractory to anti-tumour necrosis factor alpha: uniti-1","volume":"10","author":"Rutgeerts","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0122|cit122","first-page":"S982","article-title":"Assessment of serum c-reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate-severely active Crohns disease: results from the im UNITI maintenance study","volume":"1","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"S1004","DOI":"10.1016\/S0016-5085(16)33398-4","article-title":"Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe Crohn's disease: results from the UNITI and IMUNITI phase 3 clinical trials","volume":"1","author":"Sands","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/S0016-5085(16)31326-9","article-title":"Molecular response to ustekinumab in moderate-to-severe Crohn\u2019s disease by serum protein analysis: results from UNITI-1 induction, UNITI-2 induction, and IMUNITI maintenance studies","volume":"1)","author":"Li","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MIB.0000000000000720","article-title":"A multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-13p40 mab, in moderate-service Crohn's disease refractory to anti-TFNalpha: UNITI-1","volume":"22","author":"Sandborn","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0126|cit126","article-title":"A multicenter, double-blind, placebo-controlled ph3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn's disease who are naive or not refractory to anti-TNFA: uniti-2","volume":"no volume","author":"Feagan","year":"2016","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.14309\/00000434-201710001-00718","article-title":"Response and remission after 16 weeks of ustekinumab: an all patients analysis from the UNITI Crohn's studies","volume":"112","author":"Colombel","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0128|cit128","first-page":"A308","article-title":"Response and remission after 16 weeks of ustekinumab-an all patients analysis from the UNITI Crohn\u2019s studies","volume":"5","author":"Colombel","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0129|cit129","unstructured":"A study to evaluate the safety and efficacy of ustekinumab induction therapy in patients with moderately to severely active Crohn's disease (UNITI-2) https:\/\/ClinicalTrials.gov\/show\/NCT01369342"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0130|cit130","first-page":"S","article-title":"Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn's disease studies, by population","volume":"154","author":"Ghosh","year":"2018","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0131|cit131","first-page":"S","article-title":"Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: a post-hoc analysis of the UNITI trials","volume":"154","author":"Feagan","year":"2018","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0132|cit132","first-page":"A6","article-title":"A multicenter, double-blind, placebo (pbo)- controlled ph3 study of ustekinumab (ust), a human mab to IL-12\/23P40, in pts with moderately-severely active Crohn's disease (cd) who are naive or not refractory to antitnfa: uniti-2","volume":"65","author":"Feagan","year":"2016","journal-title":"Gut"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0133|cit133","first-page":"S","article-title":"Association of ustekinumab serum concentrations and perianal fistula resolution in the Crohn's disease UNITI program","volume":"156","author":"Sands","year":"2019","journal-title":"Gastroenterology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0134|cit134","first-page":"913","article-title":"Association of ustekinumab serum concentrations and perianal fistula resolution in the Crohn's disease UNITI program","volume":"7","author":"Sands","year":"2019","journal-title":"United European Gastroenterology Journal"},{"issue":"10080","key":"10.1002\/14651858.CD012751.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.14309\/01.ajg.0000776548.94565.6c","article-title":"Risankizumab as induction therapy in patients with moderately to severely active Crohn's disease who failed 1 vs >1 prior biologic treatment: results from the motivate study","volume":"116","author":"Panaccione","year":"2021","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0137|cit137","unstructured":"Efficacy, safety and pharmacokinetics of BI 655066\/ABBV-066 (Risankizumab) in patients with active, moderate-to-severe Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02031276"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.62.suppl_2.ii70","article-title":"Alpha-integrin blockade in inflammatory bowel disease","volume":"62","author":"Ghosh","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"A378","DOI":"10.1016\/S0016-5085(03)81912-1","article-title":"Quality of life improvements in a phase 2 study of natalizumab for active Crohn's disease","volume":"124","author":"Rutgeerts","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0141|cit141","first-page":"A127","article-title":"A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to \u03b14 integrin (AntegrenTM) in moderate to severely active Crohn's disease","volume":"120","author":"Antegren Publication Committee","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"A127","DOI":"10.1016\/S0016-5085(08)80627-0","article-title":"A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to \u03b14 integrin (AntegrenTM) in moderate to severely active Crohn's disease","volume":"120","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0144|cit144","first-page":"A726","article-title":"Treatment of active ulcerative colitis with a recombinant humanised antibody to alpha4 integrin (Antegren)","volume":"116","author":"Gordon","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0145|cit145","first-page":"A726","article-title":"Randomised doubleblind placebo controlled trial of recombinant humanised antibody to a4 integrin (AntegrenTM) in active Crohn's disease","volume":"116","author":"Gordon","year":"1999","journal-title":"Gastroenterology"},{"issue":"9317","key":"10.1002\/14651858.CD012751.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0147|cit147","first-page":"A615","article-title":"Infliximab maintenance therapy improves health related quality of life (HRQL) in Crohn's disease over 54 weeks","volume":"122","author":"Feagan","year":"2002","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","article-title":"C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I","volume":"35","author":"Reinisch","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0150|cit150","first-page":"A617","article-title":"Relationship between infliximab pharmacokinetics and improvement in Crohn's disease","volume":"122","author":"Fasanmade","year":"2002","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1572-0241.2003.07674.x","article-title":"The effects of infliximab maintenance therapy on health-related quality of life","volume":"98","author":"Feagan","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0152|cit152","first-page":"A615","article-title":"Infliximab treatment allows Crohn's disease to reduce or discontinue concomitant corticosteroid use: ACCENT 1 year results","volume":"122","author":"Lichtenstein","year":"2002","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0153|cit153","first-page":"A","article-title":"Maintenance infliximab (remicade) is safe, effective and steroid-sparing in Crohn's disease: preliminarry results from the ACCENT I trial","volume":"120","author":"Hanauer","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0154|cit154","first-page":"391","article-title":"Infliximab in maintenance treatment of Crohn's disease: results of the ACCENT 1 study","volume":"9","author":"Piche","year":"2002","journal-title":"Hepato-Gastro"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointestinal Endoscopy"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0156|cit156","first-page":"A618","article-title":"Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease","volume":"122","author":"Rutgeerts","year":"2002","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0158|cit158","first-page":"P284","article-title":"Change in c-reactive protein correlates with change in endoscopic measures of disease activity in Crohn's disease patients treated with infliximab","volume":"122","author":"Sands","year":"2002","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD012751.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of c-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD012751.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1185\/030079905X65457","article-title":"Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease","volume":"21","author":"Geboes","year":"2005","journal-title":"Current Medical Research and Opinion"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0161|cit161","first-page":"A150","article-title":"Infliximab treatment results in the sustained reduction of inflammatory markers in the mucosa of patients with Crohn's disease","volume":"122","author":"Geboes","year":"2002","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0163|cit163","unstructured":"A safety and efficacy study of infliximab (remicade) in patients with moderate to severe active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00207662"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"A228","DOI":"10.1136\/gutjnl-2012-302514c.108","article-title":"Induction of remission with adalimumab in patients with moderate Crohn's disease: subanalysis of CLASSIC I","volume":"61","author":"Sandborn","year":"2012","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0166|cit166","first-page":"S436","article-title":"Induction of remission with adalimumab in patients with moderate Crohn's disease: subanalysis of CLASSIC I","volume":"106","author":"Sandborn","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"P816","DOI":"10.1016\/S2468-1253(21)00252-1","article-title":"Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial","volume":"6","author":"Hanauer","year":"2021","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(20)33649-0","article-title":"BI 695501 demonstrates similar efficacy and comparable safety to adalimumab reference product in patients with active Crohn's disease: final analysis of the phase III VOLTAIRE-CD study","volume":"158","author":"Hanauer","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.14309\/01.ajg.0000613176.48811.7c","article-title":"Biosimilar BI 695501 demonstrates non-inferior efficacy and comparable safety to adalimumab reference product in patients with active Crohn's disease","volume":"114","author":"Hanauer","year":"2019","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0170|cit170","first-page":"439","article-title":"Bi 695501 demonstrates similar efficacy and comparable safety to adalimumab reference product in patients with active Crohn\u2019s disease: final analysis of the phase III VOLTAIRE-CD study","volume":"8","author":"Hanauer","year":"2020","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0171|cit171","unstructured":"BI 695501 versus humira in patients With active Crohn's disease: a trial comparing efficacy, endoscopic improvement, safety, and immunogenicity https:\/\/ClinicalTrials.gov\/show\/NCT02871635"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0172|cit172","unstructured":"BI 695501 versus Humira in patients with active Crohn's disease: a trial comparing efficacy, endoscopic improvement, safety, and immunogenicity http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-000612-14-CZ 2016"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1002\/14651858.CD012751.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus Jr","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"10340","key":"10.1002\/14651858.CD012751.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0176|cit176","unstructured":"A study to assess the efficacy and safety of risankizumab in participants with moderately to severely active Crohn's disease who failed prior biologic treatment https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03104413"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.14309\/01.ajg.0000776548.94565.6c","article-title":"S754 risankizumab as induction therapy in patients with moderately to severely active Crohn\u2019s disease who failed 1 vs> 1 prior biologic treatment: results from the MOTIVATE study","volume":"116","author":"Panaccione","year":"2021","journal-title":"Official Journal of the American College of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0179|cit179","unstructured":"A randomized, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the safety and efficacy of CP-690,550 for induction therapy in subjects with moderate to severe Crohn's disease http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-001733-16-HR 2014"},{"issue":"18","key":"10.1002\/14651858.CD012751.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012751.pub2-BIB0181|cit181","first-page":"A188","article-title":"Anti-tumor necrosis factor antibody cA2 treatment induces clinical remissions in patients with active Crohn's disease","volume":"39","author":"Deventer","year":"1996","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0182|cit182","unstructured":"Phase III randomized study of anti-tumor necrosis factor chimeric monoclonal antibody (cA2) for patients with enterocutaneous fistulae as a complication of Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00004941"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD012751.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0186|cit186","first-page":"A211","article-title":"Pharmacodynamic results from a phase 3 study evaluating natalizumab therapy of active Crohn's disease (ENACT-1)","volume":"126","author":"Lawrance","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/j.1572-0241.2007.01508.x","article-title":"Health-related quality of life during natalizumab maintenance therapy for Crohn's disease","volume":"102","author":"Sandborn","year":"2007","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0188|cit188","first-page":"A462","article-title":"Safety, tolerability and immunogenicity of natalizumab in a phase III study of active Crohn's disease therapy (ENACT-1)","volume":"126","author":"Enns","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"A523","DOI":"10.1016\/S0016-5085(09)62409-4","article-title":"The efficacy of natalizumab in Crohn's disease patients who smoke","volume":"136","author":"Plevy","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0190|cit190","first-page":"A208","article-title":"Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1)","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0191|cit191","unstructured":"Safety and efficacy of natalizumab in the treatment of Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00032786"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0192|cit192","unstructured":"Safety and efficacy of natalizumab in the treatment of Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00032799"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0193|cit193","first-page":"A","article-title":"Efficacy assessment of natalizumab in patients with Crohn's disease and prior history of anti-TNF therapy: results from ENACT-1","volume":"126","author":"Sandborn","year":"2004","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD012751.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. [Summary for patients in Ann Intern Med. 2007 Jun 19;146(12):I20; PMID: 17470825]","volume":"146","author":"Sandborn","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0195|cit195","unstructured":"A multi-center, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody adalimumab for the induction of clinical remission in subjects with moderate to severe Crohn's disease who have lost response or are intolerant to infliximab https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002934-20\/BE"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0196|cit196","unstructured":"Study of the human anti-TNF monoclonal antibody adalimumab for the induction of clinical remission in subjects with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00105300"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/apt.12930","article-title":"Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECISE 3 study","volume":"40","author":"Sandborn","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0199|cit199","unstructured":"Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00552058"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"S508","DOI":"10.14309\/00000434-201410002-01719","article-title":"Crohn's disease behavior as a risk factor for loss of maintenance of remission in patients treated with certolizumab pegol: results from the PRECISE 3 study","volume":"102","author":"Rubin","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0201|cit201","first-page":"A107","article-title":"Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo controlled phase III study (PRECISE 1)","volume":"130","author":"Sandborn","year":"2006","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0202|cit202","first-page":"A479","article-title":"Safety and tolerability of subcutaneous (sc) certolizumab pegol in active Crohn's disease (CD): results from two phase III studies (PRECISE program)","volume":"106","author":"Schreiber","year":"2006","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0203|cit203","first-page":"A503","article-title":"Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: PRECISE 3 efficacy results","volume":"132","author":"Schreiber","year":"2007","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0204|cit204","first-page":"S441","article-title":"Fecal calprotectin concentration and clinical remission in patients with active Crohn's disease treated with certolizumab pegol: results from PRECISE 1","volume":"106","author":"Sandborn","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/ajg.2009.199","article-title":"Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn\u2019s disease","volume":"104","author":"Feagan","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.14309\/00000434-201010001-01156","article-title":"Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo-controlled trial","volume":"105","author":"Sandborn","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0207|cit207","unstructured":"A study to test the effect of cdp870 in the treatment of Crohn\u2019s disease over 26 weeks, comparing CDP870 to a dummy drug (placebo) https:\/\/ClinicalTrials.gov\/show\/NCT00152490"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD012751.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease","volume":"104","author":"Toedter","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00054725-200802001-00032","article-title":"A multicenter, randomized, phase 2A study of human monoclonal antibody to IL- 12\/23P40 (CNTO 1275) in patients with moderately to severely active Crohn's disease","volume":"14","author":"Sandborn","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0211|cit211","first-page":"A51","article-title":"A multicenter, randomized, phase 2a study of human monoclonal antibody to IL-12\/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease","volume":"132","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0212|cit212","unstructured":"A study of the safety and efficacy of ustekinumab (CNTO 1275) in participants with Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00265122"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0215|cit215","first-page":"S439","article-title":"Antibodies against certolizumab pegol (CZP), plasma concentrations of CZP and efficacy in patients with Crohn\u2019s disease receiving continuous CZP therapy with or without concomitant immunosuppressants","volume":"106","author":"Sandborn","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.14309\/00000434-201010001-01156","article-title":"Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo-controlled trial","volume":"105","author":"Sandborn","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0217|cit217","first-page":"S565","article-title":"Efficacy of certolizumab pegol induction and maintenance therapy in patients with Crohn\u2019s disease not in remission following active or placebo induction","volume":"1","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD012751.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/00054725-201112002-00076","article-title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease","volume":"17","author":"Sands","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S1873-9946(12)60320-1","article-title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease","volume":"6","author":"Feagan","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0221|cit221","unstructured":"A study of safety and effectiveness of ustekinumab in patients with moderate to severe active Crohn's disease who have been previously treated with anti-TNF therapy https:\/\/ClinicalTrials.gov\/show\/NCT00771667"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0222|cit222","unstructured":"A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ustekinumab therapy in subjects with moderately to severely active Crohn\u2019s disease previously treated with TNF antagonist therapy https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-000649-77\/results"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.14309\/00000434-201410002-01679","article-title":"Evaluation of an interim Crohn's disease outcome measure (PRO-2) based on 2 patient-reported components (stool frequency, abdominal pain) of the Crohn\u2019s disease activity index (CDAI) in the ustekinumab CERTIFI study","volume":"109","author":"Gasink","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0016-5085(11)61056-1","article-title":"Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies","volume":"140","author":"Toedter","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0225|cit225","first-page":"S713","article-title":"The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn\u2019s disease: results from the CERTIFI study","volume":"148","author":"Ding","year":"2016","journal-title":"Canadian Journal of Gastroenterology and Hepatology. Conference"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S0016-5085(11)60443-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase2b study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the CERTIFI trial","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.14309\/00000434-201110002-01227","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12\/23P40, in patients with moderately to severely active Crohn\u2019s disease: results through week 36 from the CERTIFI trial 2011 ACG presidential poster","volume":"106","author":"Feagan","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.14309\/00000434-201110002-01227","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12\/23P40, in patients with moderately to severely active Crohn\u2019s disease: results through week 36 from the CERTIFI trial 2011 ACG presidential poster","volume":"106","author":"Feagan","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD012751.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012751.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"Study A3921043 Investigators A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2017","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2468-1253(22)00303-X","article-title":"Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial","volume":"8","author":"Sandborn","year":"2023","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.14309\/00000434-201802001-00011","article-title":"Etrolizumab as induction therapy in moderate to severe Crohn\u2019s disease: results from BERGAMOT cohort 1","volume":"113","author":"William","year":"2018","journal-title":"Official Journal of the American College of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0233|cit233","unstructured":"A study to assess whether etrolizumab is a safe and efficacious treatment for participants with moderately to severely active Crohn\u2019s disease (BERGAMOT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02394028"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s12325-020-01366-2","article-title":"Etrolizumab for the treatment of ulcerative colitis and Crohn's disease: an overview of the phase 3 clinical program","volume":"37","author":"Sandborn","year":"2020","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2468-1253(22)00303-X","article-title":"Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial","volume":"8","author":"Sandborn","year":"2023","journal-title":"Lancet Gastroenterology & Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenetrology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0237|cit237","unstructured":"A multicenter, randomized, double-blind, placebo-controlled study of ABT-494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to I http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-003240-12-HU 2015"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1650-64.e8","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012751.pub2-BIB0239|cit239","first-page":"169","article-title":"Effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: week 12 results from the phase 2 GALAXI 1 study","volume":"36","author":"Leong","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0240|cit240","first-page":"S","article-title":"The effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn's disease: week 12 results from the phase 2 GALAXI 1 study","volume":"160","author":"Sands","year":"2021","journal-title":"Gastroenterology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0241|cit241","first-page":"S","article-title":"The effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: week 12 results from the phase 2 GALAXI 1 study","volume":"160","author":"D'Haens","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012751.pub2-BIB0242|cit242","first-page":"495","article-title":"Early pro-2 symptom remission following guselkumab induction treatment: results through week 12 of the phase 2 GALAXI 1 study","volume":"9","author":"Reinisch","year":"2021","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0243|cit243","first-page":"497","article-title":"Patient-reported outcomes of response and remission following guselkumab induction treatment as measured by the inflammatory bowel disease questionnaire: results through week 12 of the phase 2 GALAXI 1 study","volume":"Suppl 8","author":"Panes","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0244|cit244","unstructured":"A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn\u2019s disease (GALAXI) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03466411"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012751.pub2-BIB0245|cit245","first-page":"497","article-title":"Patient-reported outcomes of response and remission following guselkumab induction treatment as measured by the inflammatory bowel disease questionnaire: results through week 12 of the phase 2 GALAXI 1 study","volume":"9","author":"Panes","year":"2021","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.14309\/01.ajg.0000776524.51669.ed","article-title":"Early pro-2 symptom remission following guselkumab induction treatment: results through week 12 of the phase 2 GALAXI 1","volume":"116","author":"Afzali","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0247|cit247","first-page":"115","article-title":"The effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: week 12 results from the phase 2 GALAXI-1 study","volume":"36","author":"D'Haens","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0248|cit248","first-page":"124","article-title":"The effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately-to-severely active Crohn's disease: week 12 results from the phase 2 GALAXI-1 study","volume":"36","author":"Sands","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.14309\/01.ajg.0000776960.58058.bf","article-title":"Patient-reported outcomes of response and remission following guselkumab induction treatment as measured by the inflammatory bowel disease questionnaire: results through week 12 of the phase 2 GALAXI 1 study","volume":"116","author":"Rubin","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012751.pub2-BIB0250|cit250","first-page":"495","article-title":"Early pro-2 symptom remission following guselkumab induction treatment: results through week 12 of the phase 2 GALAXI 1","volume":"9","author":"Reinisch","year":"2021","journal-title":"United European Gastroenterology Journal"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0251|cit251","first-page":"64","article-title":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Crohn's disease: week 12 interim analyses from the phase 2 GALAXI 1 study","volume":"8","author":"Sandborn","year":"2020","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0252|cit252","first-page":"S344","article-title":"Afzali A, Sandborn WJ, Hisamatsu T, Weisel K, Gonzalez S, Frustaci ME, et al","volume":"116 (Suppl)","author":"Early pro-2 symptom remission following guselkumab induction treatment: results through week 12 of the phase 2 GALAXI 1 study","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012751.pub2-BIB0253|cit253","first-page":"108","article-title":"Effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn's disease: week 12 results from the phase 2 GALAXI 1 study","volume":"36","author":"Andrews","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012751.pub2-BIB0254|cit254","first-page":"108","article-title":"Effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn's disease: week 12 results from the phase 2 GALAXI 1 study","volume":"36","author":"Andrews","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD012751.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study","volume":"23","author":"\u00a0Blank","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"A378","DOI":"10.1016\/S0016-5085(03)81913-3","article-title":"Relationship of antibodies to infliximab to duration of response and infusion reactions for Crohn's disease patients receiving episodic infliximab retreatment in ACCENT I","volume":"124","author":"Wagner","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"A380","DOI":"10.1016\/S0016-5085(03)81923-6","article-title":"Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II trial","volume":"124","author":"Sands","year":"2003","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study","volume":"2","author":"Sands","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0261|cit261","first-page":"A466","article-title":"Maintenance treatment with infliximab reduces the likelihood of hospitalization in patients with fistulizing Crohn's disease","volume":"126","author":"Sands","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/S0016-5085(03)80303-7","article-title":"Infliximab pharmacokinetics and improvement in fistulizing Crohn's disease","volume":"124","author":"Fasanmade","year":"2003","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"A379","DOI":"10.1016\/S0016-5085(03)81920-0","article-title":"Infliximab does not result in increased abscess development infistulizing Crohn's disease: results from ACCENT II","volume":"124","author":"Deventer","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0264|cit264","unstructured":"A study of the safety and efficacy of infliximab (Remicade) in subjects with fistulizing Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00207766"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study","volume":"23","author":"Sands","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0267|cit267","unstructured":"Safety and efficacy of natalizumab in combination with remicade in the treatment of Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00055536"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ibd.21159","article-title":"Randomized, double-blind, placebo-controlled trial of the oral interleukin-12\/23 inhibitor apilimod mesylate for treatment of active Crohn's disease","volume":"16","author":"Sands","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1873-9946(13)60012-4","article-title":"Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial","volume":"7","author":"Sands","year":"2013","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S1873-9946(14)60098-2","article-title":"Efficacy of induction treatment with vedolizumab for patients with Crohn's disease who have experienced tumour necrosis factor antagonist failure or are tumour necrosis factor antagonist naive","volume":"8","author":"Sandborn","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0272|cit272","first-page":"S68","article-title":"Vedolizumab in combination with steroids for induction therapy in Crohn's disease: an exploratory analysis of the GEMINI 2 and GEMINI 3 studies","volume":"12","author":"Sands","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ibd\/izy384","article-title":"Vedolizumab in combination with corticosteroids for induction therapy in Crohn's disease: a post hoc analysis of GEMINI 2 and 3","volume":"25","author":"Sands","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/ecco-jcc\/jjaa153","article-title":"Early intervention with vedolizumab on longer term surgery rates in Crohn's disease: post hoc analysis of the GEMINI Phase 3 and long-term safety programs","volume":"15","author":"Dulai","year":"2020","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0275|cit275","first-page":"S","article-title":"Efficacy of vedolizumab induction therapy in patients with Crohn's disease who have experienced tumor necrosis factor antagonist failure or are tumor necrosis factor antagonist naive","volume":"146","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naive to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.14309\/00000434-201710001-00769","article-title":"Evaluation of the use of vedolizumab in 46 patients with inflammatory bowel disease in Brazil","volume":"112","author":"Steinwurz","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0278|cit278","unstructured":"Study of vedolizumab in patients with moderate to severe Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT01224171"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/00054725-201212001-00059","article-title":"Vedolizumab induction therapy for patients with crohn's disease and prior anti-tnf antagonist failure: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"18","author":"Sands","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0280|cit280","unstructured":"A phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction of clinical response and remission by vedolizumab in patients with moderate to severe Crohn's disease http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-016488-12-HU"},{"issue":"10342","key":"10.1002\/14651858.CD012751.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.14309\/01.ajg.0000776612.28121.af","article-title":"Health-related quality of life with ustekinumab vs adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn\u2019s disease: LBDQ in the SEAVUE study","volume":"116","author":"Loftus","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0283|cit283","first-page":"S395","article-title":"Health-related quality of life with ustekinumab vs adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn's disease: Promis-29 in the SEAVUE study","volume":"116","author":"Lewis","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0284|cit284","first-page":"1215","article-title":"The pharmacokinetics and immunogenicity of ustekinumab and adalimumab in patients with moderate-to-severe Crohn\u2019s disease: results from the SEAVUE study","volume":"9","author":"Danese","year":"2021","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0285|cit285","unstructured":"Safety and efficacy of adalimumab versus ustekinumab for one year https:\/\/ClinicalTrials.gov\/show\/NCT03464136"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1053\/j.gastro.2021.06.040","article-title":"775d ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn's disease: the SEAVUE study","volume":"161","author":"Sands","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0287|cit287","unstructured":"A study to compare the efficacy and safety of ustekinumab with adalimumab in the treatment of subjects with moderately-to-severely active Crohn's disease, not undergone treatment with biologic https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-004209-41-NL"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"102591","DOI":"10.1016\/j.clinre.2025.102591","article-title":"Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease","volume":"49","author":"Chen","year":"2025","journal-title":"Clinics and Research in Hepatology and Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0290|cit290","unstructured":"Vedolizumab intravenous (IV) compared to placebo in chinese participants with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT03234907"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0291|cit291","unstructured":"A study of mirikizumab (LY3074828) in participants with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT03926130"},{"issue":"10470","key":"10.1002\/14651858.CD012751.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0293|cit293","unstructured":"A study of guselkumab subcutaneous therapy in participants with moderately to severely active Crohn\u2019s disease (GRAVITI) https:\/\/clinicaltrials.gov\/study\/NCT05197049"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0294|cit294","article-title":"Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s disease: results from the phase 3 GRAVITI study","volume":"no volume","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0295|cit295","first-page":"i77","article-title":"OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn\u2019s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD)","volume":"19","author":"Jairath","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"issue":"21","key":"10.1002\/14651858.CD012751.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus Jr","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0297|cit297","unstructured":"Second phase 3 induction study confirms upadacitinib (RINVOQ\u00ae) improved clinical and endoscopic outcomes in patients with Crohn's disease https:\/\/news.abbvie.com\/news\/press-releases\/news-type\/rd-news\/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-and-endoscopic-outcomes-in-patients-with-crohns-disease.htm"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0298|cit298","unstructured":"A study of the efficacy and safety of upadacitnib (ABT-494) in participants with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to conventional and\/or biologic therapies https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345849"},{"issue":"11","key":"10.1002\/14651858.CD012751.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0300|cit300","unstructured":"Study of combination therapy of adalimumab and an immunomodulator for Crohn\u2019s disease(DIAMOND study) https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000006111"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0301|cit301","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"no volume","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0302|cit302","unstructured":"A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn\u2019s disease (GALAXI) https:\/\/clinicaltrials.gov\/study\/NCT03466411"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0303|cit303","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"no volume","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0304|cit304","unstructured":"A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn\u2019s disease (GALAXI) https:\/\/clinicaltrials.gov\/study\/NCT03466411"},{"issue":"391(3)","key":"10.1002\/14651858.CD012751.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0306|cit306","unstructured":"Peyrin-Biroulet L SEQUENCE 3b study risankizumab versus ustekinumab for patients with moderate to severe Crohn's disease European Gastroenterology Week (UEGW 2023) 2023"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0307|cit307","unstructured":"Study comparing intravenous (IV)\/subcutaneous (SC) risankizumab to IV\/SC ustekinumab to assess change in Crohn's Disease Activity Index (CDAI) in adult participants with moderate to severe Crohn's disease (CD) https:\/\/ClinicalTrials.gov\/show\/NCT04524611"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0308|cit308","unstructured":"A study to compare the efficacy of risankizumab and ustekinumab in subjects with moderately to severe active Crohns disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-002674-26-NL"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. [Erratum appears in Gastroenterology. 2005 Nov;129(5):1808 Note: dosage error in article text]","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"Erratum: a randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease (Gastroenterology (2005) 129 (807-818))","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00384-007-0395-7","article-title":"Certolizumab pegol, a monthly subcutaneously administered FC-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease","volume":"23","author":"Schreiber","year":"2008","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0312|cit312","unstructured":"Clinical study of CDP870\/certolizumab pegol in patients with active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00291668 2006"},{"issue":"9","key":"10.1002\/14651858.CD012751.pub2-BIB0313|cit313","first-page":"1014","article-title":"A phase 2, randomized, placebo-controlled study evaluating matrix metalloproteinase-9 inhibitor, andecaliximab, in patients with moderately to severely active Crohn\u2019s disease","volume":"12","author":"Schreiber","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0314|cit314","first-page":"A302","article-title":"Andecaliximab (anti-MMP9) induction therapy for Crohn\u2019s disease: a double-blind, randomized, placebo-controlled, phase 2 study","volume":"5","author":"Schreiber","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0315|cit315","unstructured":"Vedolizumab IV 300 mg in the treatment of fistulizing Crohn's disease (ENTERPRISE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02630966"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0316|cit316","unstructured":"A randomized double-blind phase 4 study to evaluate the safety and proportion of subjects with fistula healing in 2 dose regimens of entyvio (vedolizumab iv) in the treatment of fistulizing Crohn's disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-000852-12-ES"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0317|cit317","article-title":"Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn\u2019s disease: ENTERPRISE study","volume":"no volume","author":"Schwartz","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"15","key":"10.1002\/14651858.CD012751.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","article-title":"Infliximab improves quality of life in patients with Crohn's disease","volume":"8","author":"Lichtenstein","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0321|cit321","unstructured":"An efficacy and safety study of anti-TNF monoclonal antibody in patients with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00269854 1995"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the encore trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00054725-200802001-00033","article-title":"Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment","volume":"14","author":"Panaccione","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"A180","DOI":"10.1016\/S0016-5085(09)60811-8","article-title":"The impact of natalizumab on the quality of life of patients exposed to or failing anti-TNFalpha therapy in the ENCORE trial","volume":"136","author":"Panaccione","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0325|cit325","first-page":"507","article-title":"Natalizumab induces sustained response and remission in Crohn's patients after previous infliximab failure: results from the ENCORE trial","volume":"132","author":"Present","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0326|cit326","first-page":"A108","article-title":"Natalizumab induces sustained response and remission with active Crohn's disease: results from the ENCORE trial","volume":"130","author":"Targan","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0327|cit327","article-title":"Natalizumab induces sustained response and remission in patients with Crohn's disease activity index scores 330: results from the ENCORE trial","volume":"no volume","author":"Panaccione","year":"2007","journal-title":"UEGW Abstract Database"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0328|cit328","article-title":"Natalizumab induces sustained response and remission in Crohn's disease patients after previous anti-TNF alpha therapy failure: results from the ENCORE trial","volume":"no volume","author":"Rutgeerts","year":"2007","journal-title":"UEGW Abstract Database"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0329|cit329","article-title":"Natalizumab induces sustained response and remission in patients with active Crohn's disease: ENCORE trial results","volume":"no volume","author":"Spehlmann","year":"2006","journal-title":"UEGW Abstract Database"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0330|cit330","unstructured":"A clinical trial of natalizumab in individuals with moderately to severely active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00078611"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2468-1253(24)00272-3","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"1","author":"Vermeire","year":"2025","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0334|cit334","unstructured":"Filgotinib in the induction and maintenance of remission in adults with moderately to severely active Crohn's disease (DIVERSITY1) https:\/\/clinicaltrials.gov\/study\/NCT02914561"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2468-1253(24)00272-3","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"1","author":"Vermeire","year":"2025","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0336|cit336","unstructured":"Filgotinib in the induction and maintenance of remission in adults with moderately to severely active Crohn's disease (DIVERSITY1) https:\/\/clinicaltrials.gov\/study\/NCT02914561"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0338|cit338","first-page":"S321","article-title":"Japanese patients with moderately to severely active Crohn's disease experience improved quality of life with adalimumab treatment","volume":"138","author":"Hibi","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0340|cit340","unstructured":"Phase III study of MLN0002 (300 mg) in treatment of Crohn\u2019s disease https:\/\/ClinicalTrials.gov\/show\/NCT02038920 2014"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0341|cit341","first-page":"S","article-title":"A phase 3 study of vedolizumab for induction and maintenance therapy in Japanese patients with moderate to severe Crohn's disease","volume":"156","author":"Ogata","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a pegylated fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar ct-p13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0344|cit344","unstructured":"Demonstrate noninferiority in efficacy and to assess safety of CT-P13 in patients with active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT02096861 2014"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0345|cit345","first-page":"385","article-title":"Exposure-response relationship of subcutaneous infliximab (ct-p13 sc) in patients with active Crohn\u2019s disease and ulcerative colitis: analysis from a multicenter, randomized controlled pivotal trial","volume":"8","author":"Ye","year":"2020","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/ecco-jcc\/jjx002.098","article-title":"Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results","volume":"11","author":"Kim","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0347|cit347","first-page":"1139","article-title":"Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results","volume":"5","author":"Kim","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0016-5085(17)30571-1","article-title":"Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab (inx) in patients with active Crohn's disease: early efficacy and safety results","volume":"152","author":"Kim","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(18)30972-7","article-title":"Phase III randomized controlled trial to compare biosimilar infliximab (ct-p13) with innovator infliximab in patients with active Crohn's disease: 1-year maintenance and switching results","volume":"154","author":"Ye","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"EVIDoa2200061","DOI":"10.1056\/EVIDoa2200061","article-title":"Discontinuation of infliximab therapy in patients with Crohn\u2019s disease","volume":"1","author":"Buhl","year":"2022","journal-title":"NEJM Evidence"},{"issue":"12","key":"10.1002\/14651858.CD012751.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"e005887","DOI":"10.1136\/bmjopen-2014-005887","article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial","volume":"4","author":"Buhl","year":"2014","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0352|cit352","unstructured":"Discontinuation of infliximab therapy in patients with Crohn's disease during sustained complete remission (STOP IT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01817426"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0353|cit353","first-page":"S","article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease in sustained, complete clinical-biochemical-endoscopic remission: a double-blinded, placebo-controlled, randomized clinical trial","volume":"160","author":"Buhl","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0354|cit354","unstructured":"Discontinuation of biologic therapy (infliximab) in patients with Crohn's disease during sustained complete absence of disease activity: a Nordic multi-center, double blinded, randomized, placebo controlled study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-002702-51\/DK 2015"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"52\u201365","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0356|cit356","first-page":"A197","article-title":"Increased risk of clinical relapse is associated with longer disease duration in Crohn's disease","volume":"136","author":"Rubin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0357|cit357","unstructured":"Adalimumab for the induction and maintenance of clinical remission in subjects with Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00077779"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0358|cit358","first-page":"S68","article-title":"Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use","volume":"5","author":"Vermeire","year":"2011","journal-title":"Journal of Crohn's & Colitis"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.12499","article-title":"Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE","volume":"38","author":"Panaccione","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S1873-9946(12)60263-3","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates for adalimumab-treated patients with early Crohn's disease","volume":"6","author":"Schreiber","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0362|cit362","first-page":"S468","article-title":"Long-term maintenance of clinical remission with reduced dosing frequency of adalimumab in patients with moderate to severe Crohn's disease","volume":"138","author":"Panaccione","year":"2010","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn's disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2036.2011.04717.x","article-title":"Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease","volume":"34","author":"Kamm","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0365|cit365","first-page":"S263","article-title":"Adalimumab 160-\/80-mg induction regimen is associated with better outcomes compared with the 80-\/40-mg regimen during maintenance therapy in patients with Crohn's disease","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD012751.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","article-title":"Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease","volume":"31","author":"Panaccione","year":"2010","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.14309\/00000434-201110002-01163","article-title":"Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: pooled data from the CHARM and EXTEND trials","volume":"106","author":"Colombel","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ajg.2009.59","article-title":"Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial","volume":"104","author":"Colombel","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0369|cit369","first-page":"486","article-title":"The CHARM trial of adalimumab in Crohn's disease","volume":"2","author":"Colombel","year":"2006","journal-title":"Gastroenterology and Hepatology (Quebec)"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"A229","DOI":"10.1136\/gutjnl-2012-302514c.109","article-title":"Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: pooled data from the CHARM and EXTEND trials","volume":"61","author":"Colombel","year":"2012","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD012751.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/j.1572-0241.2008.02175.x","article-title":"Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial","volume":"103","author":"Loftus","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.14309\/00000434-201110002-01196","article-title":"Adalimumab maintenance therapy improves patient-reported outcomes in patients with moderate crohn's disease: subanalysis of CHARM","volume":"106","author":"Loftus","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ibd.21836","article-title":"Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial","volume":"18","author":"Rubin","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl SA","key":"10.1002\/14651858.CD012751.pub2-BIB0375|cit375","article-title":"Resolution of flare or nonresponse with no dosage increase in most adalimumab-treated patients with Crohn's disease","volume":"23","author":"Plevy","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"Suppl. SA","key":"10.1002\/14651858.CD012751.pub2-BIB0376|cit376","article-title":"Adalimumab treatment associated with rapid and significant improvements in health-related quality of life in patients with Crohn's disease","volume":"23","author":"Colombel","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0377|cit377","first-page":"1291","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"50","author":"Wasvary","year":"2007","journal-title":"Diseases of the Colon and Rectum"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0378|cit378","first-page":"A179","article-title":"Quality-of-life improvements in patients with Crohn's disease treated for 3 years with adalimumab in an open-label extension of CHARM","volume":"136","author":"Loftus","year":"2009","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0379|cit379","first-page":"A180","article-title":"Remission and quality-of-life improvements sustained with adalimumab in anti-TNF-naive patients with Crohn's disease: 3-year data from CHARM","volume":"136","author":"Loftus","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl SA","key":"10.1002\/14651858.CD012751.pub2-BIB0380|cit380","article-title":"Response with continued adalimumab therapy for up to 12 weeks in patients with Crohn's disease who were nonresponders at week 4","volume":"23","author":"Panaccione","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"Suppl SA","key":"10.1002\/14651858.CD012751.pub2-BIB0381|cit381","article-title":"Adalimumab maintains long-term remission in moderately to severely active Crohn's disease through 2 years","volume":"23","author":"Panaccione","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0382|cit382","first-page":"S43","article-title":"Adalimumab therapy maintains remission for up to 3 years in patients with moderately to severely active Crohn's disease: results from an open-label extension of CHARM","volume":"15","author":"Panaccione","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl SA","key":"10.1002\/14651858.CD012751.pub2-BIB0383|cit383","article-title":"Adalimumab maintenance therapy and health-related quality of life in TNF-antagonist-naive patients with Crohn's disease","volume":"23","author":"Rubin","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0384|cit384","first-page":"A652","article-title":"Maintenance of long-term remission in patients with moderately to severely active Crohn's disease treated for 3 years with adalimumab: results from the open-label ADHERE study","volume":"136","author":"Rutgeerts","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.14309\/00000434-201110002-01197","article-title":"C-reactive protein levels in moderate to severe Crohn's disease patients decreased rapidly and significantly during adalimumab therapy","volume":"106","author":"Ghosh","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.1016\/S0016-5085(13)62329-X","article-title":"Quality of life for patients with deep remission vs. clinical remission and deep remission vs. absence of mucosal ulceration: 3-year data from CHARM\/ADHERE","volume":"144","author":"Colombel","year":"2013","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1053\/j.gastro.2022.01.044","article-title":"Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results","volume":"162","author":"D\u2019Haens","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0388|cit388","unstructured":"Study to evaluate efficacy and safety of two drug regimens in subjects with moderate to severe crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT02065570"},{"issue":"20","key":"10.1002\/14651858.CD012751.pub2-BIB0389|cit389","first-page":"1946\u201360","article-title":"Ustekinumab induction therapy for Crohn's disease refractory to conventional or tumor necrosis factor antagonist therapy","volume":"375","author":"Feagan","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1053\/j.gastro.2019.06.037","article-title":"Effects of ustekinumab on histologic disease activity in patients with Crohn's disease","volume":"157","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0391|cit391","first-page":"S16","article-title":"P034 efficacy of ustekinumab in Crohn's disease at maintenence week 56: IM-UNITI STUDY...Crohn's & Colitis Congress, February 7-9, 2019, Las Vegas, Nevada","volume":"25","author":"Sandborn","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"S1004","DOI":"10.1016\/S0016-5085(16)33398-4","article-title":"Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe Crohn\u2019s disease: results from the UNITI and IMUNITI phase 3 clinical trials","volume":"150","author":"Sands","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0393|cit393","unstructured":"A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn's disease (IM-UNITI) https:\/\/ClinicalTrials.gov\/show\/NCT01369355"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"S595","DOI":"10.1016\/S0016-5085(17)32132-7","article-title":"Efficacy of ustekinumab for induction and maintenance of histological healing in patient's with Crohn's disease","volume":"152","author":"Li","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0395|cit395","first-page":"A123","article-title":"Efficacy of ustekinumab for induction and maintenance of histological healing in patient's with Crohn's disease","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012751.pub2-BIB0396|cit396","first-page":"S302","article-title":"Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn's disease patients: results from the IM-UNITI maintenance study","volume":"111","author":"Sands","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0397|cit397","first-page":"S","article-title":"Clinical characteristics, clinical response, and clinical remission status in adults treated with ustekinumab in the phase 3 UNITI studies at week 6 and week 44 by age at Crohn's disease onset","volume":"160","author":"Cohen","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ecco-jcc\/jjaa189","article-title":"Week 6 calprotectin best predicts likelihood of long-term endoscopic healing in Crohn\u2019s disease: a post-hoc analysis of the UNITI\/IM-UNITI trials","volume":"15","author":"Narula","year":"2021","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0399|cit399","first-page":"S","article-title":"Long-term (5-YEAR) maintenance of clinically meaningful improvement in health-related quality of life in patients with moderate to severe Crohn's disease treated with ustekinumab in the IM-UNITI long-term extension study","volume":"160","author":"Sandborn","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0400|cit400","unstructured":"A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn's disease http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-022760-12-NL 2011"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ecco-jcc\/jjy055","article-title":"The effects of ustekinumab on health-related quality of life in patients with moderate to severe Crohn's disease","volume":"12","author":"Sands","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0402|cit402","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0403|cit403","first-page":"S16","article-title":"Efficacy of ustekinumab in Crohn\u2019s disease at maintenence week 56: IM-UNITI study","volume":"25","author":"Sandborn","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1093\/ecco-jcc\/jjy222.467","article-title":"Efficacy of ustekinumab in Crohn\u2019s disease at maintenence week 56: IM-UNITI study","volume":"13","author":"Sandborn","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0405|cit405","first-page":"A22","article-title":"Long term efficacy and safety of ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years","volume":"66","author":"Sandborn","year":"2017","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1016\/S0016-5085(17)32105-4","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through two years","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.14309\/01.ajg.0000704628.43493.6d","article-title":"Efficacy and safety of ustekinumab for Crohn's disease through 5 years: final results from the IM-UNITI long-term extension","volume":"115","author":"Sandborn","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0409|cit409","first-page":"A32","article-title":"A ph3 randomised, multicenter, double-blind, placebo (PBO)-controlled study of ustekinumab (UST) maintenance therapy in moderate-severe Crohn's disease (CD) pts: results from IM-Uniti","volume":"66","author":"Sandborn","year":"2016","journal-title":"Gut"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0410|cit410","first-page":"A121","article-title":"Efficacy and safety of ustekinumab for Crohn\u2019s disease: results from IM-UNITI long-term extension through 3 years","volume":"6","author":"Sandborn","year":"2018","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0411|cit411","first-page":"A23","article-title":"Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate-severe Crohn's disease patients: results from IM-UNITI maintenance study","volume":"66","author":"Sands","year":"2017","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0412|cit412","first-page":"S24","article-title":"Safety of ustekinumab with and without concomitant corticosteroids or immunosuppressants in patients with moderately-to-severely active Crohn's disease","volume":"113","author":"Sands","year":"2018","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1093\/ecco-jcc\/jjx180.408","article-title":"Combined clinical and biological response concomitant CRP and faecal calprotectin reductions in induction and maintenance from the phase 3 ustekinumab Crohn's disease studies","volume":"12","author":"Colombel","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.14309\/00000434-201710001-00658","article-title":"Tolerability of ustekinumab in induction and maintenance for the treatment of Crohn's disease","volume":"112","author":"Loftus","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012751.pub2-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.14309\/00000434-201802001-00101","article-title":"Tolerability of ustekinumab in induction and maintenance for the treatment of Crohn\u2019s disease","volume":"113","author":"Lofus","year":"2018","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0416|cit416","first-page":"A3","article-title":"Exposure-response to SC ustekinumab in moderate-severe Crohn\u2019s disease: results from the IM-UNITI maintenance study","volume":"5","author":"Adedokun","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0417|cit417","first-page":"S157","article-title":"A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn's disease patients: results from IM-UNITI","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1093\/ecco-jcc\/jjx002.590","article-title":"Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease","volume":"11","author":"Li","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0419|cit419","first-page":"108","article-title":"Long-term (5-year) maintenance of clinically meaningful improvement in health-related quality of life in patients with moderate to severe Crohn's disease treated with ustekinumab in the IM-UNITI long-term extension study","volume":"36","author":"Sandborn","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"10340","key":"10.1002\/14651858.CD012751.pub2-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0421|cit421","unstructured":"A study of the efficacy and safety of risankizumab in participants with Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03105102"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0422|cit422","unstructured":"Ferrante M Panaccione R Feagan B Sandborn W Pan\u00e9s J Peyrin-Biroulet L OP008 - Efficacy and safety of open-label maintenance therapy with subcutaneous risankizumab in patients with moderate-to-severe Crohn\u2019s disease UEG Week Virtual 2021, October 3-5 2021"},{"issue":"9317","key":"10.1002\/14651858.CD012751.pub2-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"10086","key":"10.1002\/14651858.CD012751.pub2-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0425|cit425","unstructured":"The NOR-SWITCH study https:\/\/ClinicalTrials.gov\/show\/NCT02148640"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/ecco-jcc\/jjx002.099","article-title":"Biosimilar infliximab (ct-p13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial","volume":"11","author":"Jorgensen","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0427|cit427","first-page":"4389","article-title":"Biosimilar infliximab (ct-p13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway","volume":"68","author":"Goll","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/joim.12880","article-title":"Long-term efficacy and safety of biosimilar infliximab (ct-p13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial","volume":"285","author":"Goll","year":"2019","journal-title":"Journal of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0430|cit430","unstructured":"A prospective randomized controlled trial comparing infliximab-antimetabolites combination therapy to anti-metabolites monotherapy and infliximab monotherapy in Crohn\u2019s disease patients in sustained steroid-free remission on combination therapy https:\/\/ClinicalTrials.gov\/show\/NCT02177071 2015"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"i001","DOI":"10.1093\/ecco-jcc\/jjab232.000","article-title":"Withdrawal of infliximab or anti-metabolite therapy in Crohn\u2019s Disease patients in sustained remission on combination therapy: a randomized unblinded controlled trial (SPARE)","volume":"16","author":"Louis","year":"2022","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0432|cit432","first-page":"A27","article-title":"Treatment de-escalation in Crohn\u2019s disease patients in remission under infliximab and immunosuppressant therapy: the SPARE trial","volume":"71","author":"Louis","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.14309\/00000434-201010001-01176","article-title":"Effect of disease duration on \"deep remission\": results from the EXTEND trial","volume":"105","author":"Colombel","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0437|cit437","first-page":"S41","article-title":"Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: results from EXTEND","volume":"5","author":"Colombel","year":"2011","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.14309\/00000434-201410002-01611","article-title":"Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from extend","volume":"109","author":"Reinisch","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1873-9946(14)60058-1","article-title":"Evaluation of site versus central assessment of endoscopies in Crohn's disease: comparison using data from EXTEND","volume":"8","author":"Rutgeerts","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/S1873-9946(14)60692-9","article-title":"Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: data from EXTEND","volume":"8","author":"Sandborn","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S1873-9946(12)60277-3","article-title":"Importance of deep remission compared with mucosal healing only: results from EXTEND","volume":"6","author":"Sandborn","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.14309\/00000434-201010001-01190","article-title":"Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: data from extend","volume":"105","author":"Colombel","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/ibd\/17.supplement1.S44","article-title":"Effect of disease duration on 'deep remission': results from the EXTEND trial","volume":"17","author":"Colombel","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0444|cit444","first-page":"S","article-title":"Evaluation of site versus central assessment of endoscopies in Crohn\u2019s disease: comparison using data from EXTEND","volume":"1","author":"Rutgeerts","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1136\/gut.2011.239301.290","article-title":"Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: data from EXTEND","volume":"60","author":"Sandborn","year":"2011","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0446|cit446","first-page":"118","article-title":"Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: data from EXTEND","volume":"29","author":"Sandborn","year":"2014","journal-title":"Journal of Gastroenterology and Hepatology (Australia)"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0447|cit447","first-page":"S","article-title":"Adalimumab achieves efficacy in mucosal healing regardless of baseline disease severity in patients with Crohn's disease: data from EXTEND","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.14309\/00000434-201010001-01208","article-title":"Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn's disease: data from EXTEND","volume":"105","author":"Sandborn","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0449|cit449","first-page":"A537","article-title":"Characterization of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn's disease from EXTEND","volume":"1","author":"Reinisch","year":"2014","journal-title":"United European Gastroenterology Journal"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0450|cit450","first-page":"151","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"12","author":"Balzola","year":"2012","journal-title":"Inflammatory Bowel Disease Monitor"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0451|cit451","first-page":"S518","article-title":"Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND","volume":"138","author":"Colombel","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.14309\/00000434-201410002-01610","article-title":"Clinical benefit of adalimumab dose adjustment for patients with moderately to severely active Crohn's disease in EXTEND","volume":"109","author":"Colombel","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0453|cit453","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","article-title":"Adalimumab induces deep remission in patients with Crohn's disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0454|cit454","first-page":"S164","article-title":"Crohn's disease mucosal healing in adalimumab-treated patients is affected by disease duration: results from EXTEND","volume":"138","author":"Sandborn","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0455|cit455","first-page":"S41","article-title":"Identification of subgroups of adalimumab-treated patients with Crohn's disease who experience high rates of deep remission","volume":"5","author":"Colombel","year":"2011","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0456|cit456","first-page":"A116","article-title":"Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease - first results of the EXTEND trial","volume":"136","author":"Rutgeerts","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00054725-200912002-00036","article-title":"Sustained mucosal healing in adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: results of the EXTEND trial","volume":"15","author":"Rutgeerts","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0458|cit458","first-page":"S85","article-title":"Early mucosal healing status predicts long-term clinical benefits for adalimumab-treated patients with moderate to severe Crohn's disease","volume":"138","author":"Rutgeerts","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0459|cit459","first-page":"S60","article-title":"Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease: data from EXTEND","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0460|cit460","first-page":"S61","article-title":"Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease: data from extend","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0461|cit461","unstructured":"Effects of adalimumab on mucosal healing in subjects with Crohn's disease involving the colon https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00348283"},{"issue":"18","key":"10.1002\/14651858.CD012751.pub2-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0463|cit463","first-page":"A586","article-title":"Efficacy of natalizumab in maintaining clinical response and remission in Crohn\u2019s disease: comparison of sustained response and remission rates through 12 months vs point-in-time response and remission rates at month 12","volume":"128","author":"Sandborn","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"A179","DOI":"10.1016\/S0016-5085(09)60809-X","article-title":"The impact of natalizumab on the quality of life of patients exposed to or failing anti-TNFalpha therapy in the ENACT-2 trial","volume":"136","author":"Feagan","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0465|cit465","first-page":"A587","article-title":"Maintenance therapy with natalizumab (ENACT-2) for patients with active Crohn's disease despite immunosuppressant use","volume":"128","author":"Targan","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0466|cit466","first-page":"A584","article-title":"Efficacy of natalizumab in patients with Crohn's disease and prior history of infliximab therapy: 12-month results from ENACT-2","volume":"128","author":"Panaccione","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0467|cit467","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/SGA.0b013e3181bb1484","article-title":"Health-related quality-of-life evaluation of Crohn disease patients after receiving natalizumab therapy","volume":"32","author":"Dudley-Brown","year":"2009","journal-title":"Gastroenterology Nursing"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0468|cit468","first-page":"A","article-title":"Maintenance therapy with natalizumab does not require use of concomitant iImmunosuppressants for sustained efficacy in patients with active Crohn's disease: results from the ENACT-2 study","volume":"130","author":"Sandborn","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD012751.pub2-BIB0469|cit469","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0470|cit470","first-page":"S88","article-title":"Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease","volume":"5","author":"Colombel","year":"2011","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0471|cit471","unstructured":"Remission in subjects with Crohn's disease, 1 year phase https:\/\/ClinicalTrials.gov\/show\/NCT00055497"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0472|cit472","unstructured":"Remission in subjects with Crohn's disease, open label extension https:\/\/ClinicalTrials.gov\/show\/NCT01070303 2002"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"A181","DOI":"10.1016\/S0016-5085(09)60814-3","article-title":"Certolizumab pegol effectiveness in Crohn's disease patients with secondary failure to infliximab is independent of infliximab dosing: results from the welcome study","volume":"136","author":"Abreu","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0475|cit475","unstructured":"Certolizumab in Crohn's disease patients with loss of response or intolerance to infliximab https:\/\/ClinicalTrials.gov\/show\/NCT00308581"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"A27","DOI":"10.1016\/S0016-5085(09)60126-8","article-title":"Welcome: A randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate to severe Crohn's disease with secondary failure to infliximab","volume":"136","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1097\/01.MIB.0000442971.65229.5b","article-title":"Erratum: P-145 welcome 54-week open-label extension: efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))","volume":"20","author":"Feagan","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"A179","DOI":"10.1016\/S0016-5085(09)60808-8","article-title":"Certolizumab pegol improves health-related quality of life in Crohn's disease patients for whom infliximab treatment was not successful: results from the welcome study","volume":"136","author":"Feagan","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0479|cit479","first-page":"S13","article-title":"Efficacy of certolizumab pegol is not affected by baseline anti-infliximab antibody status in patients with Crohn's disease with secondary infliximab failure","volume":"15","author":"Sandborn","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00054725-201112002-00069","article-title":"Crohn's disease patients with persistently elevated crp plasma concentration have higher rates of remission with certolizumab pegol 400 mg every2 weeks vs every 4 weeks","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0481|cit481","first-page":"S263","article-title":"Crohn's disease patients with persistently elevated crp plasma concentration have higher rates of remission with certolizumab pegol 400 mg every 2 weeks vs. every 4 weeks","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2036.2010.04568.x","article-title":"Randomised clinical trial: Improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab","volume":"33","author":"Feagan","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0483|cit483","first-page":"S430","article-title":"Certolizumab pegol is efficacious in crohn's disease patients who have failed infliximab regardless of concomitant therapy or reason for failure","volume":"23","author":"Fedorak","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD012751.pub2-BIB0484|cit484","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/Nejmoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0485|cit485","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/Nejmoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0486|cit486","first-page":"S","article-title":"Symptomatic improvement with vedolizumab therapy for Crohn\u2019s disease stratified by disease activity and prior tumor necrosis factor antagonist failure: post hoc analyses from the GEMINI 2 trial","volume":"160","author":"Dubinsky","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients With Crohn's disease.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD012751.pub2-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study","volume":"23","author":"\u00a0Blank","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"A378","DOI":"10.1016\/S0016-5085(03)81913-3","article-title":"Relationship of antibodies to infliximab to duration of response and infusion reactions for Crohn's disease patients receiving episodic infliximab retreatment in ACCENT I","volume":"124","author":"Wagner","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0491|cit491","unstructured":"A study of the safety and efficacy of infliximab (Remicade) in subjects with fistulizing Crohn's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00207766"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/S0016-5085(03)80303-7","article-title":"Infliximab pharmacokinetics and improvement in fistulizing Crohn's disease","volume":"124","author":"Fasanmade","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"A379","DOI":"10.1016\/S0016-5085(03)81920-0","article-title":"Infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from ACCENT II","volume":"124","author":"Deventer","year":"2003","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0495|cit495","first-page":"A466","article-title":"Maintenance treatment with infliximab reduces the likelihood of hospitalization in patients with fistulizing Crohn's disease","volume":"126","author":"Sands","year":"2004","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study","volume":"2","author":"Sands","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0497|cit497","doi-asserted-by":"crossref","first-page":"A380","DOI":"10.1016\/S0016-5085(03)81923-6","article-title":"Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II trial","volume":"124","author":"Sands","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0498|cit498","unstructured":"A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT03466411"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study","volume":"23","author":"Sands","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease. [Erratum appears in N Engl J Med. 2007 Sep 27;357(13):1357]","volume":"357","author":"Schreiber","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"Suppl SA","key":"10.1002\/14651858.CD012751.pub2-BIB0501|cit501","article-title":"Certolizumab pegol is effective in the treatment of Crohn\u2019s disease patients with open fistulas","volume":"23","author":"Khaliq-Kareemi","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2036.2010.04509.x","article-title":"Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study","volume":"33","author":"Schreiber","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2036.2010.04360.x","article-title":"Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease","volume":"32","author":"Hanauer","year":"2010","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0504|cit504","first-page":"S24","article-title":"Fecal calprotectin concentration and clinical response to certolizumab pegol inpatients with active Crohn's disease: results from PRECiSE 2","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0505|cit505","first-page":"S441","article-title":"Inflammatory biomarkers and clinical remission in patients with active Crohn\u2019s disease: results from PRECiSE 2","volume":"106","author":"Sandborn","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0506|cit506","first-page":"S23","article-title":"Baseline corticosteroid use and corticosteroid-free clinical remission in Crohn\u2019s disease patients treated with certolizumab pegol in the PRECISE 2 trial","volume":"18","author":"Sandborn","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.14309\/00000434-201110002-01173","article-title":"Formation of autoantibodies in patients with moderate to severe Crohn\u2019s disease, receiving continuous and interrupted certolizumab pegol (CZP) therapy with or without concomitant immunosuppressants","volume":"106","author":"Scherl","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data","volume":"105","author":"Schreiber","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0509|cit509","first-page":"S165","article-title":"Certolizumab pegol is effective at maintaining response and remission in patients with fistulising Crohn's disease: 3-year results from the PRECiSE 3 study","volume":"138","author":"Schreiber","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl SA","key":"10.1002\/14651858.CD012751.pub2-BIB0510|cit510","first-page":"s29","article-title":"The long-term, 30 months, efficacy and tolerability of certolizumab pegol therapy for crohn's disease","volume":"23","author":"Feagan","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1365-2036.2011.04636.x","article-title":"Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol","volume":"33","author":"Feagan","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD012751.pub2-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2010.01.014","article-title":"Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months","volume":"8","author":"Lichtenstein","year":"2010","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0513|cit513","first-page":"S165","article-title":"Certolizumab pegol demonstrates efficacy in maintaining response and remission in patients with active Crohn's disease regardless of their immunosuppressant treatment status at entry to the PRECiSE 2 study","volume":"138","author":"Schreiber","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0514|cit514","first-page":"S14","article-title":"Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation: 3-year results from the PRECiSE 4 study","volume":"15","author":"Sandborn","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.14309\/00000434-201010001-01153","article-title":"Long-term maintenance of remission with no dose escalation aft er re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naive to anti-TNF treatment: 4-year results from the precise 4 study","volume":"105","author":"Sandborn","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0516|cit516","first-page":"S60","article-title":"Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naive to anti-TNF treatment: 4-year results from PRECiSE","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0517|cit517","first-page":"S439","article-title":"Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation: 1-year results from PRECiSE 4","volume":"106","author":"Sandborn","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0518|cit518","unstructured":"Study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo), following 3 doses of active drug (CDP870) https:\/\/ClinicalTrials.gov\/show\/NCT00152425"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous versus intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"SUPPL 8","key":"10.1002\/14651858.CD012751.pub2-BIB0520|cit520","first-page":"553","article-title":"Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease: post-hoc analysis of pre\/post switch outcomes from a multicentre, randomised controlled pivotal","volume":"9","author":"Schreiber","year":"2021","journal-title":"United European Gastroenterology Journal"},{"issue":"SUPPL 8","key":"10.1002\/14651858.CD012751.pub2-BIB0521|cit521","first-page":"549","article-title":"Comparison of combination subcutaneous infliximab and an immunomodulator versus subcutaneous infliximab monotherapy: Post-hoc analysis of a randomised clinical trial","volume":"9","author":"D'Haens","year":"2021","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0522|cit522","unstructured":"A phase I study to evaluate pharmacokinetics, efficacy and safety of CT-P13 subcutaneous in patients with active Crohn's disease and ulcerative colitis https:\/\/ClinicalTrials.gov\/show\/NCT02883452"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0523|cit523","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/gutjnl-2011-300755","article-title":"Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised switch trial","volume":"61","author":"Van Assche","year":"2012","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0524|cit524","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0016-5085(10)60390-3","article-title":"Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab. The prospective randomized SWITCH study","volume":"138","author":"Van Assche","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0525|cit525","first-page":"150","article-title":"Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised switch trial","volume":"12","author":"Balzola","year":"2012","journal-title":"Inflammatory Bowel Disease Monitor"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0526|cit526","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0527|cit527","first-page":"12","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the visible 2 randomised trial","volume":"1","author":"Vermeire","year":"2021","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0528|cit528","first-page":"S","article-title":"Early onset of response with intravenous vedolizumab induction therapy in patients with moderately to severely active Crohn's disease treated in the visible 2 study","volume":"160","author":"D'Haens","year":"2021","journal-title":"Gastroenterology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0529|cit529","first-page":"S","article-title":"Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with Crohn's disease: results from the phase 3 visible 2 study","volume":"158","author":"D'Haens","year":"2020","journal-title":"Gastroenterology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0530|cit530","first-page":"409","article-title":"Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with Crohn\u2019s disease: results from the phase 3 visible 2 trial","volume":"8","author":"D'Haens","year":"2020","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0531|cit531","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1093\/ecco-jcc\/jjy222.623","article-title":"Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn's disease: results from VISIBLE 1 and 2","volume":"13","author":"Loftus","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0532|cit532","first-page":"S","article-title":"Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn's disease: results from VISIBLE 1 and 2","volume":"156","author":"Loftus","year":"2019","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0533|cit533","first-page":"115","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in patients with moderately to severely active Crohn's disease: results of the VISIBLE 2 study","volume":"35","author":"Vermeire","year":"2020","journal-title":"Journal of Gastroenterology and Hepatology (Australia)"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0534|cit534","first-page":"S","article-title":"950 the visible 2 phase 3 study of efficacy and safety of vedolizumab SC for moderate-to-severe Crohn's disease","volume":"158","author":"Vermeire","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0535|cit535","unstructured":"Efficacy and safety of vedolizumab subcutaneous (SC) as maintenance therapy in Crohn's disease (CD) https:\/\/ClinicalTrials.gov\/show\/NCT02611817"},{"issue":"10","key":"10.1002\/14651858.CD012751.pub2-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2468-1253(24)00272-3","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"1","author":"Vermeire","year":"2025","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0537|cit537","unstructured":"Filgotinib in the induction and maintenance of remission in adults with moderately to severely active Crohn's disease (DIVERSITY1) https:\/\/clinicaltrials.gov\/study\/NCT02914561"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0538|cit538","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ibd\/izab099","article-title":"Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0539|cit539","first-page":"A307","article-title":"Similar trial-efficacy of infliximab-biosimilar compared to infliximab-biological in patients with inflammatory bowel disease in remission-a randomized, controlled, double blind, phase 4 noninferiority trial","volume":"5","author":"Volkers","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0540|cit540","unstructured":"Efficacy and safety of infliximab-biosimilar (inflectra) compared to infliximab-innovator (remicade) in patients with inflammatory bowel disease in remission: the SIMILAR trial https:\/\/ClinicalTrials.gov\/show\/NCT02452151 2015"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0541|cit541","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0542|cit542","doi-asserted-by":"crossref","unstructured":"A study of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn\u2019s disease https:\/\/ClinicalTrials.gov\/show\/NCT00445432 2007","DOI":"10.1016\/S0739-5930(08)70100-4"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0543|cit543","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s11096-024-01739-5","article-title":"A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS)","volume":"46","author":"Young","year":"2024","journal-title":"International Journal of Clinical Pharmacy"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0545|cit545","unstructured":"Inflammatory bowel disease (IBD) reference product (humira-adalimumab) and biosimilar product (imraldi-adalimumab) cross over study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004967-30"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0546|cit546","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/01.MIB.0000480181.61935.67","article-title":"Randomized clinical trial for clinical response evaluation in Crohn's disease: infliximab versus adalimumab","volume":"22","author":"Baima","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0547|cit547","unstructured":"A phase IIIb multicenter, open-label induction and double-blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab\u2019 fragment of humanized antibody to tumor necrosis factor (TNF) over 26 weeks in subjects suffering from Crohn\u2019s disease (CD) with prior loss of response or intolerance to infliximab https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2005-004104-37"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0548|cit548","unstructured":"A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn\u2019s disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001913-41\/results"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0549|cit549","unstructured":"A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients\u2019 satisfaction with Certolizumab pegol treatment in moderate to severe Crohn\u2019s disease when treatment is administered in two different settings : either at hospital or at home http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-003239-21-FR"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0550|cit550","unstructured":"Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial - Azorix-trial http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-001131-35-NL"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0551|cit551","unstructured":"Azathioprine maintenance treatment versus infliximab maintenance treatment in Crohn's disease patients in remission (Azorix trial) https:\/\/trialsearch.who.int\/?TrialID=NTR1404"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0552|cit552","unstructured":"Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn's disease - CHAMP http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-004926-18-DE"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0553|cit553","unstructured":"Adalimumab intralesional in intestinal strictures of crohn's disease patients https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2012-001723-12"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0554|cit554","unstructured":"A clinical study to evaluate the safety and effectiveness of JNJ-64304500 as an add-on therapy to standard of care biologic therapy with anti-tumor necrosis factor alpha or anti-interleukin 12\/23 in Responder Not Remitter participants with active Crohn's disease http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2020-002701-26-IT"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0555|cit555","first-page":"642","article-title":"The advantages of early application of infliximab to Crohn's disease treatment","volume":"47","author":"Yu","year":"2012","journal-title":"Chinese Pharmaceutical Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0556|cit556","unstructured":"GMA (granulocyte and monocyte adsorption) early combined with azathioprine vs Infliximab plus azathioprine for induction of remission in active Crohn's disease : an open randomized trial https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000006728"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0557|cit557","unstructured":"Optimization of adalimumab switch therapy for loss of response with infliximab in Crohn's disease -OASISstudy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000010524"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0558|cit558","unstructured":"Corticosteroid sparing effect of certolizumab in crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT00349752"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0559|cit559","unstructured":"An open-label, multi-center trial to examine the long term safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease who have failed tapering of corticosteroids, needed corticosteroids after completion of tapering, or have successfully completed the trial C87059 (COSPAR I) https:\/\/trialsearch.who.int\/?TrialID=EUCTR2006-003871-11-DE"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0560|cit560","unstructured":"A phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (COSPAR 1) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-003870-88\/DE#D"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0561|cit561","unstructured":"Efficacy of infliximab in the treatment of patients affected by corticodependent crohn's disease (P02732) https:\/\/ClinicalTrials.gov\/show\/NCT00796250"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0562|cit562","unstructured":"Calprotectin-directed humira\u00ae maintenance therapy (CADHUM) https:\/\/ClinicalTrials.gov\/show\/NCT01674413"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0563|cit563","unstructured":"Cimzia versus mesalamine for crohn's recurrence https:\/\/ClinicalTrials.gov\/show\/NCT01696942"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0564|cit564","unstructured":"Managing infliximab reinduction after temporary discontinuation of drug https:\/\/ClinicalTrials.gov\/show\/NCT02771457"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0565|cit565","unstructured":"Thalidomide versus infliximab in new onset crohn's disease with poor prognostic factors https:\/\/ClinicalTrials.gov\/show\/NCT03221166"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0566|cit566","unstructured":"Evaluation of the clinical and immunological impact of two therapeutic strategies in chronic inflammatory diseases https:\/\/ClinicalTrials.gov\/show\/NCT03370601"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0567|cit567","unstructured":"The therapy effect of azathioprine initial or 14 weeks after combined with infliximab on CD https:\/\/ClinicalTrials.gov\/show\/NCT03393247"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0568|cit568","unstructured":"Loss of response of adalimumab biosimilar vs adalimumab original, in inflammatory bowel disease https:\/\/ClinicalTrials.gov\/show\/NCT04131322"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0569|cit569","unstructured":"A study of JNJ-64304500 as add-on therapy in participants with active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT04655807"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0570|cit570","unstructured":"Safety and efficacy of oral BT-11 in crohn's disease patients with moderate to severe disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05057273"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0571|cit571","first-page":"A225","article-title":"QAX576, an anti-interleukin (IL)-13 monoclonal antibody, for the treatment of patients with fistulising Crohn's disease (CD): results of a proof-of concept study","volume":"2","author":"Rogler","year":"2014","journal-title":"United European Gastroenterology Journal"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0572|cit572","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5217\/ir.2016.14.2.152","article-title":"Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease","volume":"14","author":"Wu","year":"2016","journal-title":"Intestinal Research"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0573|cit573","unstructured":"Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease https:\/\/ClinicalTrials.gov\/show\/NCT02015793 2013"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0574|cit574","unstructured":"Comparison between switching from intravenous to subcutaneous infliximab on the maintenance of clinical and biochemical remission in patients with inflammatory bowel disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12621001498886"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0575|cit575","unstructured":"Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12622001458729"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0576|cit576","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819874202","article-title":"Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial","volume":"12","author":"Chaparro","year":"2019","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"i50","DOI":"10.1093\/ecco-jcc\/jjac190.0037","article-title":"OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)","volume":"Supplement_1","author":"Chaparro","year":"2023","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0578|cit578","unstructured":"Anti-TNF discontinuation in patients with inflammatory bowel disease: Multicentre, prospective, randomized clinical trial and economic evaluation - EXIT https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015%E2%80%90001410%E2%80%9010%E2%80%90ES"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0579|cit579","unstructured":"Efficacy and safety of ustekinumab intravenous maintenance versus subcutaneous maintenance in Crohn's disease: a multicenter randomized controlled clinical trial https:\/\/www.chictr.org.cn\/showproj.html?proj=171522"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0580|cit580","unstructured":"A study to evaluate the effectiveness and safety of etrasimod in the treatment of active Crohn's disease http:\/\/www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=48722&EncHid=&modid=&compid=%27,%2748722det%27"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0581|cit581","unstructured":"A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-002895-14-SK"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0582|cit582","unstructured":"A study of the efficacy and safety of upadacitinib (ABT-494) in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to biologic therapy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-001226-18-PL"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0583|cit583","unstructured":"Study to evaluate the efficacy and safety of mirikizumab in patients with active Crohn's disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-004614-18-LT"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0584|cit584","unstructured":"A study to test whether BI 706321 combined with ustekinumab helps people with Crohn\u2019s Disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-004527-16"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0585|cit585","unstructured":"A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active crohn's disease (CD): AIM-CD https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-002869-18"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0586|cit586","first-page":"e042885","article-title":"Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial","volume":"11","author":"Jonkers","year":"2021","journal-title":"Gastroenterology and Hepatology (Quebec)"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0587|cit587","unstructured":"A phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter, proof-of-concept clinical study to evaluate the safety and efficacy of JNJ-64304500 as add-on therapy to standard of care biologic therapy with anti-tumor necrosis factor alpha or anti-interleukin 12\/23 in Responder Not Remitter participants with active Crohn's Ddisease (DUET) https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCT2031200406"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0588|cit588","unstructured":"Efficacy and safety of formulation switching between infliximab SC and IV in patients with Crohn's disease (CHAMELEON Study) https:\/\/cris.nih.go.kr\/cris\/search\/detailSearch.do?seq=22116&search_page=L&search_lang=E&lang=E"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0589|cit589","unstructured":"An active and placebo-controlled study of brazikumab in participants with moderately to severely active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT03759288"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0590|cit590","unstructured":"A study of vedolizumab in adult participants with moderate to severe crohn's disease https:\/\/clinicaltrials.gov\/show\/NCT05837897"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0591|cit591","unstructured":"A randomized, double-blind, placebo-controlled trial of vedolizumab with and without upadacitinib in adults with crohn's disease: design and rationale for the VICTRIVA study https:\/\/clinicaltrials.gov\/study\/NCT06227910"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0592|cit592","first-page":"S802","article-title":"A randomized, double-blind, placebo-controlled trial of vedolizumab with and without upadacitinib in adults with crohn's disease: design and rationale for the VICTRIVA study","volume":"119","year":"2024","journal-title":"American Journal of Gastroenterology"},{"issue":"21","key":"10.1002\/14651858.CD012751.pub2-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus Jr","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"S597","DOI":"10.1016\/S0016-5085(17)32137-6","article-title":"Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis","volume":"152","author":"Feagan","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0596|cit596","first-page":"S58","article-title":"The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn's disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies","volume":"10","author":"D'Haens","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1093\/ecco-jcc\/jju027.626","article-title":"Vedolizumab for the treatment of fistulising Crohn's disease: an exploratory analysis of data from GEMINI 2","volume":"9","author":"Feagan","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0598|cit598","first-page":"S592","article-title":"Vedolizumab exposure-response relationship during induction therapy in adults with Crohn's disease","volume":"1","author":"French","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0599|cit599","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1093\/ecco-jcc\/jju027.711","article-title":"Efficacy and safety of retreatment with vedolizumab in patients with Crohn's disease","volume":"9","author":"Sands","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0600|cit600","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1093\/ecco-jcc\/jju027.740","article-title":"Infusion-related reactions with vedolizumab treatment in patients with uc or cd during the GEMINI 1 and GEMINI 2 clinical trials","volume":"9","author":"Sands","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0601|cit601","first-page":"A604","article-title":"Evaluation of patient-reported outcomes from the Crohn\u2019s disease activity index to define remission in the GEMINI 2 study","volume":"1","author":"Sandborn","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0602|cit602","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1093\/ecco-jcc\/jju027.646","article-title":"Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with Crohn's disease in GEMINI 2","volume":"9","author":"Colombel","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0603|cit603","doi-asserted-by":"crossref","first-page":"S789","DOI":"10.14309\/00000434-201510001-01857","article-title":"Corticosteroid dose reduction with vedolizumab treatment of Crohn\u2019s disease during the GEMINI 2 trial","volume":"110","author":"Loftus Jr","year":"2015","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.14309\/00000434-201710001-00668","article-title":"Vedolizumab demonstrates early symptomatic improvement in Crohn's disease (CD): a GEMINI 2 post hoc analysis","volume":"112","author":"Feagan","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0605|cit605","first-page":"A237","article-title":"Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis","volume":"66","author":"Feagan","year":"2017","journal-title":"Gut"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0606|cit606","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.14309\/00000434-201410002-01618","article-title":"Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease","volume":"109","author":"Sands","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0607|cit607","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0608|cit608","unstructured":"Study of vedolizumab (MLN0002) in patients with moderate to severe Crohn's disease (first received 2 November 2008)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1093\/ecco-jcc\/jjx180.865","article-title":"Sustained clinical remission with vedolizumab in moderate-to-severe Crohn's disease: a GEMINI 2 post hoc analysis of week 14 remitters","volume":"12","author":"Hardi","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0610|cit610","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5217\/ir.2019.09160","article-title":"Efficacy and safety of vedolizumab in Crohn's disease in patients from Asian countries in the GEMINI 2 study","volume":"19","author":"Banerjee","year":"2021","journal-title":"Intestinal Research"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012751.pub2-BIB0611|cit611","first-page":"S","article-title":"Symptomatic improvement with vedolizumab therapy for Crohn\u2019s disease stratified by disease activity and prior tumor necrosis factor antagonist failure: post hoc analyses from the GEMINI 2 trial","volume":"160","author":"Dubinsky","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0612|cit612","first-page":"A254","article-title":"Corticosteroid dose reduction with vedolizumab treatment of Crohn\u2019s disease","volume":"65","author":"Loftus Jr","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0613|cit613","doi-asserted-by":"crossref","first-page":"S842","DOI":"10.1016\/S0016-5085(15)32856-0","article-title":"Effect of vedolizumab on health-related quality of life in patients with Crohn's disease","volume":"148","author":"Sandborn","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0614|cit614","doi-asserted-by":"crossref","first-page":"S624","DOI":"10.14309\/00000434-201210001-01550","article-title":"Vedolizumab induction therapy for Crohn's disease: results of GEMINI II, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial","volume":"107","author":"Sandborn","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0615|cit615","first-page":"A370","article-title":"Reductions in corticosteroid use in patients with ulcerative colitis or Crohn's disease treated with vedolizumab","volume":"108","author":"Sands","year":"2013","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0616|cit616","doi-asserted-by":"crossref","first-page":"S772","DOI":"10.1016\/S0016-5085(13)62854-1","article-title":"Efficacy of vedolizumab in Crohn's disease by prior treatment failure in GEMINI II, a randomized, placebo-controlled, double-blind, multicenter study","volume":"144","author":"Hanauer","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0617|cit617","first-page":"S274","article-title":"Vedolizumab for the treatment of fistulizing Crohn's disease: an exploratory analysis of data from GEMINI 2","volume":"148","author":"Feagan","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0618|cit618","first-page":"A17","article-title":"Efficacy of vedolizumab with and without continued immunosuppressant use in GEMINI 1 and GEMINI 2","volume":"3","author":"Feagan","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0619|cit619","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/S0016-5085(16)32724-X","article-title":"The efficacy of vedolizumab by disease activity and prior tumor necrosis factor a antagonist failure in patients with ulcerative colitis or Crohn's disease: post hoc analyses from the GEMINI 1 and GEMINI 2 studies","volume":"10","author":"D'Haens","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0620|cit620","doi-asserted-by":"crossref","first-page":"S791","DOI":"10.14309\/00000434-201510001-01862","article-title":"Efficacy of vedolizumab maintenance therapy with and without continued immunosuppressant use in GEMINI 1 and GEMINI 2","volume":"110","author":"Feagan","year":"2015","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0621|cit621","first-page":"S588","article-title":"Effects of continued vedolizumab therapy for Crohn\u2019s disease in week 6 induction therapy nonresponders","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0622|cit622","doi-asserted-by":"crossref","first-page":"S476","DOI":"10.14309\/00000434-201410002-01614","article-title":"Vedolizumab results in durable clinical remission in Crohn's disease","volume":"109","author":"Sandborn","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.14309\/00000434-201410002-01617","article-title":"Safety of vedolizumab alone or with concomitant corticosteroids and\/or immunosuppressants in patients with ulcerative colitis or Crohn's disease","volume":"109","author":"Loftus","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0624|cit624","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/01.MIB.0000438818.81129.5b","article-title":"Pharmacokinetic\/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2","volume":"19","author":"Rosario","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0625|cit625","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1873-9946(14)60083-0","article-title":"Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from the GEMINI 1 and 2 studies","volume":"8","author":"Rosario","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0626|cit626","first-page":"A537","article-title":"Durability of clinical remission with vedolizumab in Crohn's disease","volume":"1","author":"Sandborn","year":"2014","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"S792","DOI":"10.14309\/00000434-201510001-01865","article-title":"Defining remission using patient-reported outcome components of the Crohn\u2019s disease activity index: post-hoc analyses of vedolizumab data from the GEMINI 2 study","volume":"110","author":"Sandborn","year":"2015","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0016-5085(13)60071-2","article-title":"Sustained therapeutic benefit of vedolizumab throughout 1 year in Crohn\u2019s disease in GEMINI ii a randomized placebo-controlled double-blind, multicenter study","volume":"144","author":"Rutgeerts","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0629|cit629","first-page":"A67","article-title":"Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease","volume":"2","author":"Sands","year":"2014","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0630|cit630","first-page":"S278","article-title":"Efficacy and safety of retreatment with vedolizumab in patients with Crohn's disease","volume":"148","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0631|cit631","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.14309\/00000434-201310001-01676","article-title":"Reductions in corticosteroid use in patients with ulcerative colitis or Crohn's disease treated with vedolizumab","volume":"108","author":"Sands","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0632|cit632","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/ecco-jcc\/jju027.449","article-title":"Efficacy and safety of vedolizumab with advancing age in patients with Crohn's disease: results from the GEMINI 2 study","volume":"9","author":"Yajnik","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0633|cit633","doi-asserted-by":"crossref","first-page":"S790","DOI":"10.14309\/00000434-201510001-01860","article-title":"Efficacy and safety of vedolizumab with advancing age in patients with Crohn\u2019s disease: results from the GEMINI 2 study","volume":"110","author":"Yajnik","year":"2015","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0634|cit634","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/01.MIB.0000480260.28955.65","article-title":"The effect of vedolizumab on extraintestinal manifestations in patients with Crohn's disease in GEMINI 2","volume":"22","author":"Rubin","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0635|cit635","first-page":"S277","article-title":"Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with Crohn's disease from GEMINI 2","volume":"148","author":"Colombel","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0636|cit636","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.14309\/00000434-201210001-01542","article-title":"Vedolizumab maintenance therapy for Crohn's disease: results of GEMINI II, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial","volume":"107","author":"Hanauer","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0637|cit637","first-page":"A82","article-title":"Safety of vedolizumab alone or with concomitant corticosteroids and\/or immunosuppressants in patients with ulcerative colitis or Crohn's disease","volume":"2","author":"Colombel","year":"2014","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1093\/ecco-jcc\/jju027.418","article-title":"Effect of vedolizumab on health-related quality of life (HRQOL) in patients with Crohn's disease","volume":"9","author":"Sandborn","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"issue":"144","key":"10.1002\/14651858.CD012751.pub2-BIB0639|cit639","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/S0016-5085(13)60410-2","article-title":"Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn's disease","volume":"5","author":"Colombel","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012751.pub2-BIB0640|cit640","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/S0016-5085(15)30763-0","article-title":"Infusion-related reactions with vedolizumab treatment in patients with UC or CD during the GEMINI 1 and GEMINI 2 clinical trials","volume":"148","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0641|cit641","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/S1873-9946(14)60617-6","article-title":"Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6","volume":"8","author":"Sandborn","year":"2014","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0642|cit642","doi-asserted-by":"crossref","first-page":"S1100","DOI":"10.1016\/S0016-5085(19)39712-4","article-title":"The impact of early disease control with vedolizumab on surgery rates among patients with Crohn's disease: a post hoc analysis of the GEMINI trials","volume":"156","author":"Dulai","year":"2019","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0643|cit643","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0016-5085(13)60071-2","article-title":"Sustained therapeutic benefit of vedolizumab throughout 1 year in Crohn\u2019s disease in GEMINI ii a randomized placebo-controlled double-blind, multicenter study","volume":"144","author":"Rutgeerts","year":"2013","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0644|cit644","doi-asserted-by":"crossref","first-page":"S803","DOI":"10.1016\/S0016-5085(16)32721-4","article-title":"Response and remission rates with up to 3 years of vedolizumab treatment in patients with Crohn's disease","volume":"150","author":"Vermeire","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012751.pub2-BIB0645|cit645","first-page":"A147","article-title":"Corticosteroid dose reduction with vedolizumab treatment of Crohn\u2019s disease","volume":"65","author":"Loftus","year":"2016","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0646|cit646","unstructured":"A phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by vedolizumab (MLN0002) in patients with moderate to severe Crohn's disease http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-002783-33-EE"},{"issue":"1","key":"10.1002\/14651858.CD012751.pub2-BIB0647|cit647","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2468-1253(22)00303-X","article-title":"Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial","volume":"8","author":"Sandborn","year":"2023","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0648|cit648","volume-title":"Kontrollierte Einf\u00fchrung des Infliximab-Biosimilars CT-P13 Bei Patienten Mit Morbus Crohn und Colitis Ulcerosa in Einer Gro\u00dfen Deutschen Zentrumskohorte (Doctoral Dissertation)","author":"R\u00f6der","year":"2021"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0649|cit649","unstructured":"Evaluating efficacy and safety of subcutaneous CT-P13 (CT-P13 SC) as maintenance therapy in patients with Crohn's disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001087-30\/LV"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0650|cit650","doi-asserted-by":"crossref","first-page":"i161","DOI":"10.1093\/ecco-jcc\/jjac190.0126","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: a phase 3, randomised, placebo-controlled study (LIBERTY-CD)","volume":"17","author":"Colombel","year":"2023","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0651|cit651","unstructured":"CT-P13 (infliximab) subcutaneous administration in patients with moderately to severely active Crohn's disease https:\/\/ClinicalTrials.gov\/show\/NCT03945019"},{"issue":"8","key":"10.1002\/14651858.CD012751.pub2-BIB0652|cit652","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010233.pub3","article-title":"Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012751.pub2-BIB0653|cit653","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008414.pub3","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD012751.pub2-BIB0654|cit654","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013210.pub2","article-title":"Interventions for maintenance of surgically induced remission in Crohn\u2019s disease: a network meta-analysis","author":"Iheozor-Ejiofor","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0655|cit655","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/flgastro-2020-101405","article-title":"Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn\u2019s disease: a systematic review","volume":"12","author":"Gordon","year":"2021","journal-title":"Frontline Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0656|cit656","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.3748\/wjg.v27.i43.7572","article-title":"Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource","volume":"27","author":"Gordon","year":"2021","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0657|cit657","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2050640620967899","article-title":"Sample-size estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: a systematic review","volume":"9","author":"Iheozor-Ejiofor","year":"2021","journal-title":"UEG Journal"},{"issue":"3","key":"10.1002\/14651858.CD012751.pub2-BIB0658|cit658","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0659|cit659","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012751.pub2-BIB0660|cit660","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012751.pub2-BIB0661|cit661","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD012751.pub2-BIB0662|cit662","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/apt.70295","article-title":"Network meta-analysis: comparative efficacy of biologics and small molecules in the induction and maintenance of remission in Crohn\u2019s disease","volume":"62","author":"Shehab","year":"2025","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012751.pub2-BIB0663|cit663","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/apt.18110","article-title":"Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease","volume":"60","author":"Attauabi","year":"2024","journal-title":"Alimentary Pharmacology & Therapeutics"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:14:51Z","timestamp":1789949691000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012751.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":663,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012751.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}